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aa amino acid 
ANCL adult NCL (CLN4) 
BHK cells baby hamster kidney cells 
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CaCo-2 cells human epithelial colon (colorectal adenocarcinoma) cells  
cDNA complementary DNA 
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cLINCL classical late infantile NCL (CLN2) 
CLN1/PPT1 gene locus or gene/protein for infantile NCL 
CLN2/TPP I gene locus or gene/protein for classical late infantile NCL 
CLN3/CLN3 gene locus or gene/protein for juvenile NCL 
CLN4 gene locus for adult NCL 
CLN5/CLN5 gene locus or gene/protein for Finnish variant late infantile 
NCL 
CLN6/CLN6 gene locus or gene/protein for variant late infantile NCL 
CLN7 gene locus for Turkish variant late infantile NCL 
Cln8/Cln8 gene locus or gene/protein for mnd 
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juvenile NCL (CLN3) 
MDCK cells dog epithelial kidney cells 
mnd motor neuron degeneration 
mRNA messenger RNA 
NCL neuronal ceroid lipofuscinosis 
ORF open reading frame 
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RT-PCR reverse transcriptase PCR 
SAP sphingolipid activator protein 
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UTR untranslated region 
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Summary 
 
Northern epilepsy (Progressive epilepsy with mental retardation (EPMR), OMIM 
600143), characterized by epilepsy and progressive mental retardation, was first 
described in 1994 by Aune Hirvasniemi. A few years later it was recognized as a 
new subtype (CLN8) of the neuronal ceroid lipofuscinoses (NCLs), which comprise 
a group among the most common progressive neurodegenerative disorders in 
childhood, characterized by accumulation of storage material in many tissues, 
especially in neurons. Prior to this study the CLN8 locus was localized to a short 
interval on chromosome 8p23 by linkage analysis and physical mapping. 
 
In this work, the CLN8 gene underlying EPMR was identified and characterized. 
CLN8 contains three exons and is ubiquitously expressed in human tissues. All 
Finnish patients carry a homozygous missense mutation c.70G>C in CLN8, 
resulting in an arginine to glycine substitution at codon 24 (R24G), allowing 
molecular confirmation of the clinical diagnosis. In addition, a homozygous 
frameshift mutation in the orthologous mouse Cln8 gene, underlying a phenotype 
of motor neuron degeneration (mnd), was characterized. Later, our group 
characterized four new mutations in CLN8 in a subset of patients of Turkish origin 
with variant late infantile NCL, suggesting that Turkish vLINCL patients without a 
CLN8 defect represent a distinct clinical and genetic entity (CLN7) among the 
NCLs.    
 
Towards understanding the normal and disturbed function of the CLN8 protein, 
encoded by the CLN8 gene, the subcellular localization of wild-type and mutant 
CLN8 proteins was analyzed in non-neuronal cells. The CLN8 protein is predicted 
to be a transmembrane protein with several transmembrane domains. In 
transiently and stably transfected non-neuronal cells it is an endoplasmic 
reticulum (ER) resident protein which partially localizes to the ER-Golgi 
intermediate compartment (ERGIC). CLN8 contains a C-terminal ER retention 
signal KKRP, which targets the protein from the ERGIC to ER. Mutant CLN8 
proteins, representing three different missense mutations found in patients, 
localized to the ER and ERGIC in transiently transfected BHK cells suggesting that 
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these mutations do not result in disturbed targeting of CLN8. On the contrary, 
the mutant CLN8 protein representing the mouse mnd mutation, predicting a 
truncated polypeptide, was only detected in the ER.  
 
In all NCL disorders, the most severe damage involves the central nervous 
system, and therefore the subcellular localization of wild-type and mutant CLN8 
proteins was next analyzed in neuronal cells using Semliki Forest virus-mediated 
expression of CLN8. By immunofluorescence analysis in hippocampal primary 
neurons CLN8 was localized in the ER and was visualized both in the dendrites 
and the axon. However, in polarized epithelial CaCo-2 cells CLN8 was 
basolaterally targeted, and in subcellular fractions of mouse brain the 
endogenous mouse Cln8 was fractionated differently from ER/ERGIC proteins. 
This suggests that in the central nervous system, part of CLN8 may be targeted to 
a specialized ER subcompartment or outside the ER. Three different missense 
mutations found in patients did not change the localization of CLN8 in 
hippocampal primary neurons and thus, like in non-neuronal cells, the primary 
defect of these mutations is likely to be due to disturbed functional properties of 
CLN8. 
 
The mouse Cln8 gene is highly homologous with human CLN8. Cln8 is ubiquitously 
expressed in both embryonic and adult mouse tissues. mRNA in situ hybridization 
analysis of whole mouse embryos showed Cln8-specific expression in developing 
brain, dorsal root ganglia and the developing gastrointestinal tract. In postnatal 
mouse brain Cln8 expression was developmentally regulated, being highest in 
hippocampal regions CA1 and CA3 at developmental stages P5 and P10. In the 
hippocampal electrical kindling model of epilepsy Cln8 expression was rapidly up-
regulated suggesting a protective role for Cln8 during epileptic seizures. 
 
Identification of CLN8 has enabled the molecular confirmation of the clinical 
diagnosis of EPMR and other CLN8-associated NCL phenotypes. Defining the 
subcellular localization of CLN8 in non-neuronal and neuronal cells as well as 
determining the spatiotemporal expression of Cln8 are important steps towards 
understanding the molecular mechanisms underlying NCLs.   
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Introduction 
 
Neuronal ceroid lipofuscinoses (NCLs) are a group of inherited neurological 
disorders characterized by accumulation of storage material in many tissues, 
especially in neurons. The first description of four siblings with the clinical 
features of NCL, epilepsy, motor dysfunction, dementia, and progressive visual 
decline, was published in 1826 (Stengel, 1826) and after that patients with 
similar clinical findings were described by a number of other clinicians. NCLs 
were first classified into a group of disorders termed amaurotic familial idiocy 
(AFI) characterized by progressive psychomotor deterioration and blindness 
(Sachs, 1896). In 1963, the storage material in NCLs was reported to be 
autofluorescent and resemble ceroid and lipofuscin (Zeman and Alpert, 1963), 
and the term neuronal ceroid lipofuscinosis was introduced to distinguish these 
disorders from the other AFI disorders (Zeman and Dyken, 1969). Today, eight 
different subtypes of NCLs are characterized and their incidence in the US has 
been estimated at 1:12500 (Rider and Rider, 1988). Four of these subtypes, INCL, 
vLINCLFin, JNCL and EPMR, belong to the Finnish disease heritage and are more 
prevalent in Finland than in other populations. 
 
Northern epilepsy (Progressive epilepsy with mental retardation (EPMR, OMIM 
600143), characterized by epilepsy and progressive mental retardation, was first 
described in 1994 (Hirvasniemi et al., 1994). To date, 26 EPMR patients, all 
originating from the Kainuu region in Northern Finland, have been diagnosed. In 
1994 our group published the chromosomal localization of the gene underlying 
EPMR, the subject of this study (Tahvanainen et al., 1994). EPMR was recognized 
as a novel subtype (CLN8) of NCLs in 2000, when neuropathological analysis of 
patient brain autopsy material revealed intraneuronal accumulation of 
cytoplasmic autofluorescent granules (Herva et al., 2000).  
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Review of the literature 
1 Neuronal ceroid lipofuscinoses  
 
The neuronal ceroid lipofuscinoses (NCLs) are a group of inherited 
neurodegenerative disorders clinically characterized by progressive mental and 
motor retardation, epilepsy, visual failure and premature death (Santavuori, 
1988; Haltia, 2003). NCLs are pathologically characterized by accumulation of 
intracytoplasmic autofluorescent material in many tissues, notably in neurons. 
On the basis of the ultrastructure of storage material deposits and the age of 
onset, NCLs were originally divided in four groups; infantile NCL (INCL), late 
infantile NCL (LINCL), juvenile NCL (JNCL) and adult NCL (ANCL). At present the 
human NCL disorders are divided into eight subgroups based on the known or 
predicted underlying gene locus (CLN1-CLN8) (Table 1) (Haltia, 2003). However, 
a clinical type of NCL is not always and automaticly equivalent to a genetic type 
because different mutations in the same gene may result in different clinical 
phenotypes. Therefore the classification of NCLs is somewhat illogical and may 
be changed in the future. There are also several reports of rare cases of human 
NCL: a congenital form of NCL and juvenile onset NCL with late visual 
impairment (Garborg et al., 1987; Barohn et al., 1992; Wisniewski et al., 1998). 
In addition, several animal NCL models exist. 
1.1 Clinical features 
Infantile NCL (INCL, CLN1) is the most severe form of the childhood NCLs. The 
patients usually develop normally until one year of age (Table 1). The first 
clinical feature, decreased rate of head growth, is followed by muscular 
hypotonia, clumsiness of fine motor control and microcephaly (Santavuori et al., 
1973; Santavuori et al., 1974; Santavuori et al., 1999). During the second year 
epileptic seizures begin, development starts to slow and truncal ataxia, visual 
failure and progressive loss of motor abilities appear. By the age of three the 
patients lose active movements and visual contact with the environment. The 
electroencephalogram (EEG) becomes flat by this time and the patients die at 8-
13 years. 
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Late infantile forms of NCL comprise a group of four disorders: classical late 
infantile NCL (cLINCL, CLN2), Finnish variant late infantile NCL (vLINCLFin, CLN5), 
variant late infantile NCL (vLINCL, CLN6) and Turkish variant late infantile NCL 
(vLINCLTurk, CLN7). The age of onset in cLINCL is 2-4 years (Kohlschutter et al., 
1993; Williams et al., 1999c), in vLINCLFin 5-7 years (Santavuori et al., 1982), in 
vLINCL 4-5 years (Lake and Cavanagh, 1978) and in vLINCLTurk 2-7 years (Topcu et 
al., 2004) (Table 1). The main clinical features in all variant late infantile forms 
are seizures, ataxia, myoclonus, developmental regression, mental retardation, 
decline of vision and speech impairment (Lake and Cavanagh, 1978; Santavuori et 
al., 1991; Kohlschutter et al., 1993; Williams et al., 1999a; Williams et al., 
1999c; Norio, 2003; Topcu et al., 2004). The first symptoms in vLINCLFin are 
visual failure and mental decline whereas in all other variant late infantile forms 
the first symptoms are seizures and ataxia. In cLINCL and vLINCL death usually 
occurs in middle childhood. However, approximately one third of vLINCL patients 
have a slightly later onset and a more protracted clinical course (Lake and 
Cavanagh, 1978; Elleder et al., 1997). vLINCLFin patients usually die at 14-32 
years and vLINCLTurk patients at the beginning of their second decade. 
 
Northern epilepsy (EPMR, CLN8) together with the most common form of NCL, 
juvenile NCL (JNCL, CLN3), comprise a group of juvenile onset forms of NCL. In 
JNCL the age of onset is 4-7 years and in EPMR 5-10 years (Table 1) (Santavuori, 
1988; Hirvasniemi et al., 1994). The progression in JNCL is more rapid than in 
EPMR. JNCL is characterized by progressive visual failure leading to blindness, 
progressive deterioration of short-term memory and other cognitive functions as 
well as seizures. Death occurs in the second or third decade (Santavuori, 1988). 
In JNCL, vacuolated lymphocytes are detected by light microscopy in several 
tissues, including lymphocytes and leucocytes, and this is used in the clinical 
diagnosis of JNCL (Hofmann et al., 1999a). In EPMR the main clinical features are 
seizures, mental retardation, progressive slowness, motor clumsiness and 
behavioral problems (Hirvasniemi et al., 1994; Hirvasniemi et al., 1995). Some 
patients have diminished visual acuity with no ocular abnormality. The clinical 
features of EPMR are described in detail in section 2 (see below).  
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The adult forms of NCLs (ANCL), starting at 11-50 years, are divided into two 
main forms, Kufs´ and Parry diseases (Berkovic et al., 1988a; Berkovic et al., 
1988b; Martin et al., 1999; Nijssen et al., 2002; Nijssen et al., 2003). Kufs´ 
disease is heterogeneous and mainly autosomally recessively inherited, whereas 
Parry disease is a homogenous disease entity and autosomally dominantly 
inherited (Table 1). ANCL is slowly progressive and is dominated by behavioral 
problems and dementia. Other characteristic features motor problems, epilepsy 
and ataxia. Vision is normal.   
 
The possible ninth variant of NCLs (CLN9) has been recently described in two 
Serbian and two German patients (Schulz et al., 2004). Their clinical history is 
characteristic for JNCL but CLN9-deficient cells have a distinctive phenotype. 
Other NCL forms were ruled out by sequencing the coding regions of NCL genes.  
  
Table 1. Classification, age of onset, and storage material in NCLs. 
GROD=granular osmiophilic deposits, CL=curvilinear profiles, FP=fingerprint 
profiles, RL=rectilinear profiles, SAP=sphingolipid activator protein, subunit 
c=subunit c of the mitochondrial ATP synthase.  
 
Gene 
locus 
Disease Age of onset Main accumulated 
protein  
Ultrastructural 
phenotype 
CLN1 
 
Infantile NCL (INCL)  8-13 months SAPs A and D GROD 
CLN2 
 
Classical late infantile NCL 
(cLINCL) 
2-4 years subunit c  CL 
CLN3 
 
Juvenile NCL (JNCL) 4-7 years subunit c  FP, CL, RL 
CLN4 
 
Adult NCL (ANCL) Kufs´ disease 11-50 years subunit c FP, mixed 
CLN5 Finnish variant late infantile NCL 
(vLINCLFin) 
5-7 years subunit c  FP, CL, RL 
CLN6 
 
Variant late infantile NCL 
(vLINCL) 
4-5 years subunit c  FP, CL, RL 
CLN7 Turkish variant late infantile 
NCL (vLINCLTurk) 
2-7 years subunit c CL, RL 
CLN8 Northern epilepsy (EPMR) 
 
5-10 years subunit c  CL-like, 
granular 
? Adult NCL (ANCL) Parry disease 
 
11-50 years SAP D GROD 
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1.2 Storage material  
The pathomorphological feature of all NCL disorders is the accumulation of 
intracytoplasmic periodic acid-schiff (PAS), luxol fast blue and Sudan black B 
positive autofluorescent material in many tissues, especially in neurons (Rapola, 
1993). This material consists of different protein components as well as 
accumulated lipids and membranes. In all NCL disorders the storage deposits 
have a characteristic ultrastructure, which can be granular osmiophilic deposits 
(GROD), curvilinear profiles (CL), rectilinear profiles (RL), fingerprint profiles 
(FP), granular deposits or a mixture of different profiles (Table 1). In INCL the 
ultrastructure of storage deposits is GRODs and in Parry disease (ANCL) GRODs 
and fingerprint profiles (Haltia et al., 1973; Carpenter et al., 1977; Palmer et al., 
1992; Tyynelä et al., 1993; Nijssen et al., 2003) (Table 1). In INCL the main 
protein components of the storage material are sphingolipid activator proteins 
(SAPs), also called saposins, A and D and in Parry disease the main protein 
component is SAP D (Tyynelä et al., 1993; Nijssen et al., 2003). In other NCL 
disorders the main protein component is subunit c of the mitochondrial ATP 
synthase (Table 1). In cLINCL the ultrastructure of storage material is curvilinear 
(Table 1) (Hall et al., 1991). In JNCL, vLINCL, vLINCLFin and vLINCLTurk rectilinear, 
curvilinear and fingerprint profiles are seen (Table 1) (Carpenter et al., 1977; 
Lake and Cavanagh, 1978; Santavuori et al., 1982; Tyynelä et al., 1997; Williams 
et al., 1999b; Topcu et al., 2004). In Kufs´ disease the ultrastructure of storage 
material is fingerprint and mixed (Table 1) (Martin et al., 1999). In EPMR the 
storage deposits show mainly curvilinear-like and partly granular ultrastructure 
(Herva et al., 2000). Although storage material accumulates in all tissues, the 
cellular defect is only characterized in the central nervous system (CNS). The 
mechanism underlying this phenomenon is unknown. Electron-microscopic 
detection of the storage bodies in non-neuronal cells, such as leucocytes, is one 
for the main criteria in clinical diagnosis of NCLs.  
 
1.3 Genes underlying NCLs  
All childhood onset NCL disorders are autosomally recessively inherited while 
adulthood onset NCL disorders are autosomally recessively or dominantly 
inherited. Five different genes underlying human NCLs have been characterized: 
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CLN1 on chromosome 1p32 (Järvelä et al., 1991; Vesa et al., 1995), CLN2 on 
11p15 (Sharp et al., 1997; Sleat et al., 1997), CLN3 on 16p12 (Gardiner et al., 
1990; Consortium, 1995), CLN5 on 13q22 (Klockars et al., 1996; Savukoski et al., 
1998) and CLN6 on 15q23 (Sharp et al., 1997; Gao et al., 2002; Wheeler et al., 
2002) (Table 2). In addition, the locus for the CLN8 gene, the object of this 
thesis, had been localized to a short interval on chromosome 8p23 before the 
beginning of this study (Table 2) (Tahvanainen et al., 1994; Ranta et al., 1996; 
Ranta et al., 1997). No loci have been identified for ANCL, vLINCLTurk, CLN9 or 
congenital NCL.  
 
To date numerous disease-causing mutations have been characterized in NCL 
genes: 42 in CLN1, 52 in CLN2, 31 in CLN3, 4 in CLN5 and 18 in CLN6 
(http://www.ucl.ac.uk/ncl/CLN1.html). In addition to INCL, different mutations 
in the CLN1 gene give rise to variant NCL forms with late infantile, juvenile or 
adult onset all having in common GROD-shaped storage deposits (Hofmann et al., 
1999b; Van Diggelen et al., 2001).  
 
1.4 Proteins encoded by NCL genes 
Of the five characterized NCL genes, three encode soluble lysosomal proteins and 
two encode transmembrane proteins (Table 2). The CLN1 gene encodes a soluble 
enzyme, palmitoyl protein thioesterase 1 (PPT1), which removes palmitate 
groups from S-acylated proteins in vitro (Camp and Hofmann, 1993; Camp et al., 
1994; Van Diggelen et al., 2001). The crystal structure of the PPT1 enzyme has 
been determined and this has facilitated analysis of the functional consequences 
and the genotype-phenotype correlation of different disease mutations (Bellizzi 
et al., 2000; Das et al., 2001). In COS-1 cells the PPT1 protein is targeted to 
lysosomes through the mannose-6-phosphate receptor pathway and also secreted 
to the growth medium (Hellsten et al., 1996; Verkruyse and Hofmann, 1996) 
whereas in neuronal cells it localizes to presynaptic regions of axons (Heinonen 
et al., 2000a; Lehtovirta et al., 2001; Ahtiainen et al., 2003), suggesting 
different functions for PPT1 in non-neuronal versus neuronal cells. PPT1 has been 
shown to depalmitoylate several neuron-specific peptides in vitro (Cho et al., 
2000) and its expression in human, mouse and rat brain is under developmental 
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control with increasing expression during maturation of the CNS (Isosomppi et 
al., 1999; Suopanki et al., 1999; Heinonen et al., 2000b). However, the function 
of PPT1 in neurons as well as the pathogenesis underlying the selective and 
dramatic loss of cortical neurons remains unknown.  
 
The CLN2 gene encodes a soluble protein tripeptidyl-peptidase I (TPP I), which 
cleaves tripeptides from the N-terminus of small peptides and localizes to 
lysosomes in non-neuronal cells (Table 2) (Sleat et al., 1997; Vines and 
Warburton, 1999; Ezaki et al., 2000a; Ezaki et al., 2000b). The intracellular 
processing and biochemical characteristics of TPP I have been thoroughly 
analyzed laying basis for the future therapeutic approaches (Haskell et al., 2003; 
Kim et al., 2003a; Golabek et al., 2004; Wujek et al., 2004). TPP I has a role in 
the lysosomal degradation of subunit c of the mitochondrial ATP synthase in 
vitro, and loss of TPP I activity in patients with cLINCL leads to lysosomal 
accumulation of subunit c. The neuronal localization and function of TPP I is 
unknown. 
 
The CLN3 gene encodes a transmembrane CLN3 protein, which has been reported 
to localize in several cell compartments including endosomes/ lysosomes, 
endoplasmic reticulum, the Golgi complex as well as cell membranes and the 
nucleus in non-neuronal cells (Table 2) (Järvelä et al., 1998; Kida et al., 1999; 
Kremmidiotis et al., 1999; Margraf et al., 1999; Mao et al., 2003). In neuronal 
cells CLN3 is transported along neuronal extensions and is targeted to 
presynaptic intracellular compartments (Table 2) (Järvelä et al., 1999; Luiro et 
al., 2001). CLN3 has also been shown to localize in lysosomes of the cell body in 
neurons and in mitochondria in the retina (Table 2) (Katz et al., 1997; Kyttälä et 
al., 2004). In the bovine brain, CLN3 immunoprecipitates with cholesterol, 
palmitic acid and Flotillin-1, suggesting localization of CLN3 in lipid rafts (Ezaki 
et al., 1999). This has also been demonstrated by biochemical methods (Rakheja 
et al., 2004). Studies with the S.cerevisiae homolog of CLN3, btn1, show that 
lack of btn1 leads to deficiencies in the intracellular and vacuolar levels of the 
basic amino acids (aa) arginine and lysine. Therefore, the underlying lysosomal 
defect in JNCL may be due to alteration in the transport of basic amino acids 
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into lysosomes (Kim et al., 2003b). The yeast model has also provided clues to 
other roles for CLN3, including regulation of lysosomal pH (Pearce et al., 1999; 
Chattopadhyay et al., 2003).  
 
The CLN5 gene encodes a soluble lysosomal CLN5 protein which was earlier 
predicted to be an integral transmembrane protein (Table 2) (Isosomppi et al., 
2002; Vesa et al., 2002; Holmberg et al., 2004). In addition, overexpressed CLN5 
seems to be partially secreted from BHK-21 cells (Isosomppi et al., 2002). Mouse 
Cln5 is mostly targeted to lysosomes but is also detected in the ER in COS-1 and 
HeLa cells and in mouse primary neurons (Table 2) (Holmberg et al., 2004). In 
mouse brain, Cln5 is expressed in several different neuronal cell types and 
localizes predominantly to the neuronal cell soma (Holmberg et al., 2004). Both 
human and rodent CLN5 expression is under developmental control, with 
increasing expression during maturation of the CNS (Heinonen et al., 2000b; 
Holmberg et al., 2004). The function of the CLN5 protein is unknown.  
 
The CLN6 gene encodes an ER-resident protein (CLN6) with several predicted 
transmembrane domains and of unknown function (Table 2) (Gao et al., 2002; 
Wheeler et al., 2002; Heine et al., 2004; Mole et al., 2004). Degradation of 
endocytosed arylsulfatase A protein is strongly reduced in all mutant CLN6 cell 
lines, suggesting that defects in the CLN6 protein lead to lysosomal dysfunctions, 
which may result in lysosomal accumulation of storage material (Heine et al., 
2004). In addition, manganese-dependent superoxide dismutase (MnSOD) is 
specifically and significantly increased in fibroblasts and brain extracts of vLINCL 
patients (Heine et al., 2003). 
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Table 2. NCL genes and gene products 
Gene 
locus 
Gene 
location 
Gene 
product 
Transmembrane
/ soluble  
Localization in non-
neuronal cells  
Localization in neuronal 
cells 
CLN1  1p32 PPT1 soluble 
 
lysosomes synaptic regions of axons 
CLN2  
 
11p15 TPP I soluble lysosomes 
 
? 
CLN3 16p12 CLN3 transmembrane several different cell 
compartments 
presynaptic compartments, 
mitochondria, lysosomes 
CLN4 
 
? ? ? ? 
 
? 
CLN5 
  
13q22 CLN5 soluble lysosomes 
  
lysosomes, ER 
CLN6 
 
15q23 CLN6 transmembrane ER 
 
? 
CLN7 
 
? ? ? ? ? 
CLN8 8p23 CLN8 ? ?  ? 
 
 
How mutations in different NCL proteins with different cellular localizations and 
functions result in accumulation of storage deposits in the cells and different NCL 
phenotypes remains unknown. One possibility is that all NCL proteins, residing in 
a secretory pathway, function in the same metabolic pathway (Fig. 1). There is 
evidence that at least the CLN5 protein interacts directly with CLN2 and CLN3 
proteins. (Vesa et al., 2002). However, further studies are needed to 
characterize possible shared cellular mechanisms between all NCL proteins. 
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Figure1. Localization of NCL proteins in different compartments of the secretory 
pathway in non-neuronal cells. 
 
 
 
1.5 Mouse models for NCLs   
Various naturally occuring animal forms of NCLs exist including dog, cat, sheep, 
goat, cow and mouse. Several genes underlying these animal NCLs have been 
characterized. These include the Cln6 gene, which underlies the neuronal ceroid 
lipofuscinosis (nclf) phenotype in the mouse and the cathepsin D gene, 
underlying the phenotype of congenital ovine NCL (Tyynelä et al., 2000; Gao et 
al., 2002; Wheeler et al., 2002). In addition, the gene underlying the motor 
neuron degeneration (mnd) mouse, has been characterized in this theses. 
Identifying the genes underlying NCLs has facilitated the production of gene-
targeted NCL mouse models. The development of mouse models is an important 
step towards elucidating underlying disease mechanisms and testing potential 
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treatment strategies. To date, there are two different spontaneously occurring 
mouse models and eight gene-targeted mouse models (Table 3). 
 
The mnd mouse is a naturally occuring mouse model for NCL (Table 3, see also I). 
It was first thought to be a mouse model for amyotropic lateral sclerosis (ALS) 
due to progressive degeneration of the motor system (Messer and Flaherty, 1986; 
Messer et al., 1987). Later, the mnd mouse was shown to exhibit the same 
pathological abnormalities as human NCL patients, autofluorescent intraneuronal 
inclusions immunoreactive with antibodies against subunit c of mitochondrial ATP 
synthase and retinal degeneration (Table 3) (Bronson et al., 1993; Messer et al., 
1993). Other characteristic features for mnd are neurofilament redistribution in 
spinal motor neurons, accumulation of ubiquitin deposits, loss of GABAergic 
interneurons and changes in ionotropic glutamate receptors (Callahan et al., 
1991; Mazurkiewicz et al., 1993; Cooper et al., 1999; Mennini et al., 2002). 
Contrary to human NCL patients, epilepsy is not a prominent feature in mnd 
mice, and the brain of mnd mice appears to remain relatively intact (Messer and 
Plummer, 1993). The age of onset and progression of the disease depend on the 
background strain. In a C57Bl/6J background, subtle degenerative changes in the 
retina are present as early as postnatal (P) day 15 with increased number of 
pyknotic nuclei in the outer nuclear layer (ONL) and decreased thickness of the 
ONL and rod inner and outer segments (Messer et al., 1993). The retinal 
degeneration is nearly complete by 6 months of age, when the motor neuron 
abnormalities are just beginning, leading to severe spastic paralysis and 
premature death at the age of 10-12 months (Messer and Flaherty, 1986; Messer 
et al., 1993). In an AKR background approximately 40% of the mnd/mnd F2 
progeny show early onset, by the age of 4.5-5 months, and premature death by 
the age of 7 months (Messer et al., 1995; Messer et al., 1999). 
 
The neuronal ceroid lipofuscinosis (Nclf) mouse is another naturally occuring 
mouse model for NCL (Bronson et al., 1998). Nclf is caused by a homozygous one 
base pair insertion in the Cln6 gene and is a mouse model for human vLINCL 
(CLN6; Table 3) (Gao et al., 2002; Wheeler et al., 2002). Nclf mice exhibit a very 
similar phenotype to mnd and are characterized by accumulation of storage 
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material in many cell types, progressive ataxia, myelination defects, 
neurodegeneration, neuromuscular defects and progressive retinal atrophy early 
in life (Table 3) (Bronson et al., 1998). In late stages of the disease Nclf mice 
develop severe cerebral gliosis and have severe degeneration of long tracts in the 
spinal cord and brain stem. By 6 months of age the peripheral outer retina is 
severely affected, and by around 9 months the entire retina is atrophied and 
paralysis and death occur (Bronson et al., 1998; Chang et al., 2002). 
 
A gene-targeted mouse model for human INCL (CLN1), the Cln1 null mutant 
mouse, develop spasticity, myoclonic jerking, seizures, progressive motor 
abnormalities and an accumulation of GROD-shaped autofluorescence storage 
material throughout the brain, along with neuronal loss and apoptosis, leading to 
death by 10 months of age (Table 3) (Gupta et al., 2001). The CNS of Cln1 null 
mouse exhibits reduced volume of both cortical and subcortical regions and a 
dramatic reduction in cortical and hippocampal interneuron number (Bible et al., 
2004). In addition, these mice develop widespread astrocytosis and localized 
microglial activation in restrected cortical and subcortical regions (Bible et al., 
2004). INCL patients develop seizures and GROD-shaped accumulations, and 
suffer a progressive loss of motor activities and a massive loss of neurons. 
Therefore the Cln1 null mouse is a good model to mimic INCL. Recently, another 
mouse model for INCL, Cln1(∆ex4) carrying the major Finnish mutation, has been 
produced (Jalanko et al., in press). Similarly to human INCL patients, GROD-
shaped autofluorescent storage deposits are present in the cells of Cln1(∆ex4) 
mice. Cln1(∆ex4) mice show progressive motor abnormalities and die 
prematurately.  
 
A gene-targeted mouse model for human cLINCL (CLN2), carrying a missense 
mutation (Arg477His) in the Cln2 protein, has been recently reported (Sleat et 
al., 2003) (Table 3). Preliminary observations of these mice suggest heavily 
reduced TPP I activity in brain and liver as well as a neurological deficit 
mimicking well the LINCL phenotype in human (Table 3) (Sleat et al., 2003).  
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Three different gene-targeted mouse models for human JNCL (CLN3) have been 
produced; two Cln3 null mice (Katz et al., 1999; Mitchison et al., 1999) and one 
with approximately 1 kb deletion in the Cln3 gene (Cotman et al., 2002) (Table 
3). The Cln3 null mice develop accumulation of autofluorescent material 
containing subunit c of mitochondrial ATP synthase as a major protein component 
(Katz et al., 1999; Mitchison et al., 1999). No severe behavioral abnormalities or 
seizures have been observed in animals up to 25 weeks of age (Katz et al., 1999). 
However, some animals show poor balance and an unsteady gait at the time of 
weaning (Katz and Johnson, 2001). Cln3 null mice develop neuropathological 
abnormalities with the loss of certain cortical interneurons and hypertrophy of 
many interneuron populations in the hippocampus as well as increased activity of 
TPP I in the brain (Table 3) (Mitchison et al., 1999). These mice, however, do not 
seem to have impaired vision, a character typical of human JNCL (Seigel et al., 
2002). In summary, Cln3 null mice have milder phenotype than JNCL patients. 
The third JNCL mouse model is a Cln3 (∆ex7/8) "knock-in" mouse carrying the 
major disease causing mutation in human patients, an approximately I kb 
deletion that eliminates exons 7 and 8 (Table 3) (Cotman et al., 2002). In the 
brain and peripheral tissues of Cln3 (∆ex7/8) mice several different Cln3 
messenger ribonucleic acids (mRNAs) have been detected: exon 7/8 deleted 
mRNAs encoding severely truncated polypeptides and alternatively spliced mRNA, 
ex5/7/8del, encoding a non-truncated mutant protein. The tissues of Cln3 
(∆ex7/8) mice exhibit storage deposits which are already immunoreactive to ATP 
synthase subunit c at the prenatal stage (Cotman et al., 2002). When compared 
with Cln3 null mice, Cln3(∆ex7/8) mice exhibit a more severe neurologic disease, 
with loss of photoreceptors, neurologic motor deficits and decreased survival 
(Table 3). Characterization of the ex5/7/8del mutant isoform will be required for 
a full understanding of the impact of the ∆ex7/8 mutation on the pathogenesis of 
JNCL. 
 
Cathepsin D (Ctsd) is an intracellular proteinase (Press et al., 1960). Gene-
targeted Ctsd deficient mice develop normally during the first two weeks but die 
at day 26 +/- 1 because of massive intestinal necrosis and reduced feeding 
behavior (Saftig et al., 1995) (Table 3). These mice develop seizures and 
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blindness as well as accumulation of storage material containing subunit c of 
mitochondrial ATP synthase in the CNS (Koike et al., 2000). No mutations have 
been detected in the human Cathepsin D gene.  
 
Table 3. Mouse models for NCL 
Mouse model Human 
equivalent 
Main symptoms/ findings References 
mnd 
(spontaneous) 
NCL in 
general (I)  
Progressive motor neuron degeneration, retinal 
degeneration 
Messer and Flaherty 1987; 
Bronson et al., 1993 
Nclf 
(spontaneous) 
CLN6  Progressive ataxia and retinal athropy, 
neuromuscular defects and neurodegeneration 
Bronson et al., 1998 
Cln1  
(knock out) 
CLN1  Spasticity, myoclonic jerking, seizures and 
progressive motor abnormalities 
Gupta et al., 2001 
Cln1  
(∆ex4) 
CLN1 Progressive motor abnormalities Jalanko et al., in press 
Cln2 
(Arg447His) 
CLN2  Neurological deficit (preliminary observation) Sleat et al., 2003 
Cln3  
(knock out) 
CLN3 No severe clinical symptoms, neuropathological 
abnormalities  
Mitchison et al., 1999 
Cln3  
(knock out) 
CLN3  No severe clinical symptoms, neuropathological 
abnormalities 
Katz et al., 1999 
Cln3  
(∆ex7/8) 
CLN3 Severe neurologic disease: decreased survival and  
motor deficits 
Cotman et al., 2002 
Ctsd  
(knock out) 
(Cathepsin 
D) 
Blindness, seizures and intestinal necrosis  Saftig et al., 1995;  
Koike et al., 2000 
 
1.5 Northern epilepsy (EPMR, CLN8)  
1.5.1 Clinical features 
Early development in EPMR patients is normal. At the age of 5-10 years the 
disease begins with generalized tonic-clonic seizures followed by mental decline 
(Hirvasniemi et al., 1994; Hirvasniemi et al., 1995). The frequency of seizures 
increases up to puberty despite antiepileptic medication and starts to decrease 
in young adulthood. From the age of 35 years, the frequency of seizures is usually 
none to four a year, but complete remission does not occur. Mental deterioration 
is first observed during the early school years, 2-5 years after the onset of 
epilepsy. Between 7 and 13 years of age the patients have usually been 
transferred to special classes or exempted from obligatory school education. 
EPMR patients undergo two periods with severe behavioral problems and 
enhanced mental retardation (Aune Hirvasniemi, personal communication). The 
first period takes place in puberty and the second usually between 45-55 years of 
age. Typical symptoms of the behavioral disorder are restlessness, disobedience, 
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inattentiveness and irritability (Hirvasniemi et al., 1994; Hirvasniemi et al., 
1995). Unlike in other childhood-onset NCLs, the life span of EPMR patients is not 
severely affected and the patients usually reach 60 years of age. Today there are 
altogether 10 diagnosed EPMR patients alive and the youngest patient is 14 years 
old.  
 
The physical growth of the patients is normal and no dysmorphic features have 
been detected. Young adults display slowness and clumsiness in fine motor tasks 
and after 30 years of age show obvious difficulties in equilibrium. Some patients 
have diminished visual acuity with no ocular abnormality (7/16) and dysphasic 
speech problems (3/19) (Hirvasniemi et al., 1994; Hirvasniemi et al., 1995). 
Progressive retinopathy is one of the main clinical features in human NCL forms. 
In EPMR the presence of possible progressive retinopatia has not been studied. 
 
Laboratory examinations such as carnitine, pyruvate, magnesium and serum 
electrolytes are normal, as are plasma values for N-acetyl-alpha-glucosaminidase 
and arylsulphatase (Hirvasniemi et al., 1994). Spinal fluid proteins and cytology, 
chromosomal studies, muscle biopsies and urinary screenings for amino acids, 
oligosaccharides, glycosaminoglycans and organic acids are also normal. No 
vacuolar lymphocytes have been detected in EPMR patients.  
 
1.5.2 Neuropathology 
In EPMR patients, granular Luxol fast blue, periodic acid-schiff (PAS) and Sudan 
black B positive storage material is present in the cytoplasm of neurons and, to a 
lesser extent, many other cell types (Herva et al., 2000). In the brain, this 
storage material has been found in the cytoplasm of neurons in variable amounts; 
in the isocortex, the most prominent storage is in the deep part of layer III, and 
in the hippocampus in regions CA2, CA3 and CA4 while CA1 and granular neurons 
are only mildly affected. The hippocampal region CA2 shows neuronal loss and 
neuronophagy (Herva et al., 2000). No obvious loss of axons or myelin has been 
detected in white matter. The storage deposits are strongly immunoreactive for 
subunit c of the mitochondrial ATP synthase, SAPs and amyloid β peptide. In 
Western blot and sequence analyses, the major protein component of the storage 
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material has been shown to be subunit c of mitochondrial ATP synthase (Herva et 
al., 2000). 
 
The electron-dense membrane-bound storage inclusions resemble curvilinear 
profiles, which show lamellar structure with alternating dark and light lamellae 
at higher magnification (Herva et al., 2000) (Fig. 2). In addition, small areas with 
a finely granular ultrastructure, and in one patient the presence of "lipid 
droplets", have been seen (Fig. 2).  
 
NCL disorders have been traditionally characterized as lysosomal storage 
diseases. In EPMR, however, the subcellular localization of storage deposits has 
not been determined. The subunit c protein is a transmembrane protein encoded 
by a nuclear gene ATP5G3 (Yan et al., 1994). Like other mitochondrial proteins it 
is translocated into the mitochondrial membrane. The mechanism underlying 
accumulation is unknown and the storage deposits could be, for example, 
membrane-bound fractions of the ER. Thus EPMR could belong to the group of 
endoplasmic reticulum storage diseases (ERSDs) characterized by the 
accumulation of proteins in the ER (Kim and Arvan, 1998). Further studies are 
needed to determine whether storage deposits are fractions of the ER, lysosomes 
or some other subcellular compartment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
Figure 2. Storage material in EPMR. Membrane-bound cytosomes studded with 
curved membranous profiles and "lipid droplets" are shown. Scale bar 500 nm. In 
the insert in the left upper corner scale bar 50 nm. Figure courtesy of Riitta 
Herva. 
 
       
 
 
 
2. Identification and characterization of disease genes  
2.1 The Human Genome Project 
The human genome consists of approximately 3 billion base pairs (bp) and is 
estimated to include some 30 000 genes (Table 4). The Human Genome Project 
(HGP) began in 1990 with the following goals: to identify all human genes and to 
determine all base pairs in the human genome as well as to store this information 
in public databases, to address the ethical, legal, and social issues that may arise 
from the project, and to sequence the genomes of several non-human model 
organisms (NIH publication No. 90-1590 at  
(http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml;). The 
draft sequence of the human genome was published in Nature by Human Genome 
Project (Lander et al., 2001) and in Science by the Celera company, a private 
"competitor" and later collaborator of the publicly founded HGP (Venter et al., 
2001). Two years later, in April 2003, the sequence of human genome was 
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completed (Venter et al., 2001). This genomic information has revolutioned the 
field of biomedical research and provides a new starting point for understanding 
the basic genetic makeup and how variations in genetic instructions result in 
disease (Peltonen and McKusick, 2001)  
 
2.2 Traditional identification of disease genes 
Before the complete human genome sequence was elucidated, disease genes 
were traditionally identified using positional, positional candidate, functional or 
functional candidate cloning methods. The functional cloning method can be 
employed if the amino acid sequence of a protein is at least partially known 
(Collins, 1992). The nucleotide sequence of the gene encoding this protein can 
then be predicted and identified by screening complementary deoxyribonucleic 
acid (cDNA) libraries. Another approach of functional cloning is to raise specific 
antibodies against the protein under investigation and use these to 
immunoprecipitate polyribosomes containing mRNA of a gene encoding this 
protein. This mRNA is then converted to cDNA and used to screen cDNA libraries. 
For example, the factor VIII gene was identified using this method (Gitschier et 
al., 1984). In functional candidate-gene cloning a known gene is hypothesized 
as a candidate on the basis of e.g. structural or functional relatedness to other 
known genes or knowledge on the metabolic basis of the disease. For example, 
the tumor supressor gene p53 was shown to underlie Li-Fraumeni cancer 
syndrome using this method (Malkin et al., 1990). 
 
Most often, the protein encoded by the disease gene is not known and the 
positional cloning method is used to identify a gene on the basis of its 
chromosomal localization (Collins, 1992; Collins, 1995). Using polymorphic 
markers and family sample DNAs the disease gene locus is localized in a genomic 
region by linkage analysis (Ott, 1991). The physical map of this region is then 
determined with genomic clones (Evans, 1991). Candidate disease genes in this 
chromosomal region are identified using several methods, including CpG island 
identification (Bird, 1986; Larsen et al., 1992a; Larsen et al., 1992b), exon 
amplification (Buckler et al., 1991; Church et al., 1994), direct cDNA selection 
(Lovett, 1994) and homology searches (Altschul et al., 1990; Altschul et al., 
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1997). Several different methods should be used because none of these methods 
alone is able to detect all existing genes. The final step is searching for 
mutations in candidate genes. Sequence variations are explored in a set of 
patient, carrier and control DNA samples. This can be done by several different 
methods, for example direct sequencing or single-strand conformational 
polymorphism (SSCP) analysis (Orita et al., 1989). As a classical example, the 
gene underlying cystic fibrosis was identified using the positional cloning method 
(Riordan et al., 1989; Rommens et al., 1989). The positional candidate-gene 
cloning approach relies on mapping the gene locus and searching for functionally 
attractive candidate genes in this region (Collins, 1995). The most attractive 
candidate genes are first searched for disease mutations. The FSRH gene was 
shown to underlie hypergonadotropic ovarian dysgenesis (ODG) using this method 
(Aittomäki et al., 1995). Of the human NCL genes, CLN1 has been identified by 
positional candidate gene cloning (Vesa et al., 1995), CLN2 by functional cloning 
(Sleat et al., 1997), and CLN3, CLN5 and CLN6 by positional cloning (Consortium, 
1995; Savukoski et al., 1998; Gao et al., 2002; Wheeler et al., 2002).   
 
2.3 Sequence based identification of disease genes 
The availability of the complete human genome sequence has made it possible to 
identify disease genes by the so-called sequence based identification method. 
The first initial step, linkage analysis, is the same as in the positional cloning 
method. However, the next two time-consuming steps, construction of a physical 
map and candidate gene identification, are replaced by a relatively quick 
database search (http://www.genome.ucsc.edu/) and running gene 
identification programs (e.g. NIX at http://www.hgmp.mrc.ac.uk/) on the 
internet. Once these analysis are completed, the results must be verified in the 
laboratory. Mutation screening can be done by several different methods such as 
direct sequencing or SSCP analysis.  
 
2.4 Confirming the disease gene 
A candidate disease gene has to be carefully studied to see if there is compelling 
evidence that the identified changes in it are not just neutral polymorphisms but 
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do cause the disease under investigation. In this section several different 
methods that can demonstrate that a candidate gene is likely to underly a 
disease phenotype are described (Strachan and Read, 1999; Brown, 2002). 
 
2.4.1 Mutation screening 
As described earlier, the final step in disease gene identification is searching for 
mutations, segregating with the disease phenotype, in candidate genes. 
Sequence variations are explored in a set of patient, carrier and control DNA 
samples. Mutation screening can be divided into two phases. First, scanning the 
candidate gene for mutations in patients. Secondly, mutation screening in family 
members and controls to determine whether a specific mutation is present. 
 
Several different types of disease-causing mutations can be found. Large 
deletions, inversions, nonsense and frameshift mutations as well as mutations 
affecting splicing are very likely destroy the gene function through altered 
structure of the protein or degradation of the transcript or protein produced and 
thus are usually pathogenic. A missense mutation is more likely to be pathogenic 
if it affects a part of the protein known to be functionally important. However, 
many missense mutations found in genes are neutral polymorphisms.  
 
In recessively inherited diseases patients are screened for homozygous 
mutations. These disease mutations should not be found homozygously in any 
healthy individual and carrier individuals should be heterozygous for disease 
mutations. In dominantly inherited diseases patients are screened for 
heterozygous mutations, not found in healthy control individuals. However, 
dominantly inherited diseases often have reduced penetrance and in families 
with these disorders healthy carrier individuals may be identified. To assess the 
significance of any nucleotide change, it is important to screen a large panel of 
healthy control individuals to confirm that the change found is not a 
polymorphism but truly segregates with the disease phenotype. 
 
Closely related patients usually carry the same mutation in the disease gene 
whereas a panel of unrelated patients show a variety of different mutations, 
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often including some with obviously deleterious effects on gene expression, e.g. 
deletions or frameshift mutations. Identification of several different patient 
mutations suggests that the candidate gene underlies the disease phenotype but 
eventually the functional effect should be proven by other methods. 
 
2.4.2 Restoration of normal phenotype in vitro 
Sometimes it is possible to culture a patient cell line that displays the disease 
phenotype. For some disorders, usually where mutations cause loss of function, 
the phenotype is irreversible. Transfection of a wild-type gene into the cultured 
disease cells may result in restoration of the normal phenotype by 
complementing the genetic deficiency.  
 
2.4.3 Mouse models 
Some mouse models of human diseases originate spontaneously whereas others 
have been generated by gene-targeting. Once the putative human disease gene is 
identified, gene-targeted mouse models either lacking a mouse orthologous 
disease gene ("knock out" mouse) or having a specific mutation in that gene 
("knock-in" mouse) can be generated. The mutant mice are expected to show 
some resemblance to the human disease phenotype to prove that the specific 
gene defect underlies the disease phenotype. However, it is not uncommon that 
a mouse model of a disease shows a phenotype that is considerably different 
from the human disorder.  
 
2.5 Comparative genomics 
Comparative genomics is the analysis and comparison of genomes from different 
species (Collins et al., 1998; Nobrega and Pennacchio, 2004). Genome 
researchers look at many different features when comparing genomes: gene 
location, sequence similarity, the length and number of exons, the amount of 
noncoding DNA in each genome and highly conserved regions among organisms. 
Comparative genomics has an important role in the study of human disease genes 
because the discovery of a homolog of a human disease gene in another organism 
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is often the key to understanding the biochemical function of the human gene. 
Finding a disease gene in another species can also lead to identification of an 
orthologous disease gene in humans.    
 
In addition to the human genome, genomes of numerous organisms have been 
sequenced, including  mouse (Waterston et al., 2002), fruit fly (Adams et al., 
2000), plant Arabidopsis thaliana (Initiative, 2000), roundworm (Consortium, 
1998), yeast (Goffeau et al., 1996), bacterium Escherichia coli (Blattner et al., 
1997) and the first free-living organism to be sequenced, the bacterium 
Haemophilus influenzae (Fleischmann et al., 1995) (Table 4).  Comparative 
genome sizes of these organisms are listed in Table 4.  
 
Table 4. Comparative genome sizes of several organisms. 
Organism Chromos
omes 
Estimated 
genome 
size 
Estimated 
gene number  
Estimated gene 
density gene/ base 
pairs 
Homo Sapiens (human) 
 
46 290 x 106 30 000 1/ 100 000 
Mus musculus (mouse) 
 
40 250 x 106 30 000 1/ 100 000 
Drosophila melanogaster (fruit 
fly) 
8 180 x 106 13 600 1/ 9000 
Arabidopsis thaliana  
(plant) 
5 125 x 106 25 500 1/ 4000 
Caenorhabditis elegans 
(roundworm) 
6 97 x 106 19 100 1/ 5000 
Saccharomyces cerevisiae 
(yeast) 
16 12 x 106 6 300 1/ 2000 
Escherichia coli 
(bacteria) 
1 4.7 x 106 3 200 1/ 1400 
Haemophilus influenzae  
(bacteria) 
1 1.8 x 106 1 700 1/ 1000 
 
2.5.1 Human-mouse genome sequence comparisons 
Approximately 75 million years separates humans and mice from their last 
common ancestor (Waterston et al., 2002). To date, the mouse and human 
genomes both appear to contain about 30 000 protein coding genes. However, 
the mouse genome is 14% smaller than the human genome (Table 4). The 
proportion of mouse versus human genes with no detectable homology seems to 
be less than 1%. Over 90% of the mouse and human genomes can be partitioned 
into corresponding regions of conserved synteny, reflecting segments in which 
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gene order in the most recent common ancestor has been conserved in both 
species (Waterston et al., 2002). In addition to identification of orthologus 
genes, the most standard applications of human-mouse comparative sequence 
analysis involve the annotation of previously unknown genes and the 
identification of other functionally important regions, such as gene regulatory 
elements and transcription factor binding sites (Nobrega and Pennacchio, 2004). 
Mutations in functionally important genomic regions are commonly under strong 
negative selection, and these regions are largely homologous in human and 
mouse genomes.  
 
2.6 Characterization of disease gene expression 
Identifying a disease gene is the starting point to study the normal and disturbed 
metabolism of the protein encoded by this gene. One way to provide more insight 
into the function of a protein is to study the expression of the gene during 
development. Monitoring the gene expression reveals at which developmental 
stage and in which tissues the protein encoded by this gene is needed. The 
genome of an organism is normally identical in almost every cell. The cells do not 
differ because they contain different genetic information, but because they 
express different sets of genes and thus synthesize different proteins. The 
differentiation of cells from pluripotent stem cells to fully differentiated cells is 
irreversible and takes place during early development. In addition, cells are able 
to change the expression of their genes reversibly as a response to external 
signals such as hormones or growth factors.  
 
There are numerous methods to study gene expression, including Northern blot 
(Alwine et al., 1977), quantitative real-time reverse transcriptase polymerase 
chain reaction (RT-PCR) (Ginzinger, 2002) and mRNA in situ hybridization 
analyses (Jin and Lloyd, 1997). In all of these methods, gene specific mRNA 
molecules, transcribed from a gene in a nucleus and transported to the cellular 
cytoplasm, are detected (Fig. 4). In Northern blot analysis the total mRNA pool is 
extracted from a tissue and transferred to a membrane. A gene-specific RNA 
band is then detected using a labeled, gene-specific DNA or RNA probe. In this 
method, the sizes of gene-specific transcripts can be defined, but the quantity of 
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these transcripts can not be exactly determined. In quantitative real-time RT-
PCR analysis, the total mRNA pool is extracted from a tissue sample and the 
amount of gene-specific mRNA molecules is determined using RT-PCR analysis. 
The advantage of this method is that the quantity of gene-specific mRNA 
molecules can be exactly measured. However, the sizes of mRNA molecules can 
not be determined. In mRNA in situ hybridization analysis, a gene-specific RNA 
probe is hybridized to a tissue sample on a microscope slide and monitored using 
a microscope. In this method, the spatial and temporal expression of gene-
specific mRNA can be reliably determined. Moreover, the mRNA molecules can be 
detected at the cellular level, not only at the tissue level. The disadvantage is 
that the sizes of mRNA molecules can not be determined. Both qualitative and 
quantitative methods should be used to get a reliable insight into gene 
expression. 
 
The ability to prepare gene-targeted mice lacking a specific gene ("knock out" 
mouse) or having a specific mutation in a particular gene ("knock-in" mouse) has 
been a great advantage in the analysis of gene function and gene expression 
downstream the targeted gene. Changes in gene expression levels in gene-
targeted versus control mice can be monitored during development and in 
different environmental conditions using  e.g. DNA microarrays, which monitor 
the expression of thousands of genes at the same time (Schena et al., 1995; 
DeRisi et al., 1997; Lockhart and Winzeler, 2000). DNA microarrays are glass 
slides studded with a large number of DNA fragments, each corresponding to a 
gene. The total mRNA pool is extracted from a tissue sample, converted to cDNA 
by RT-PCR and labeled with a fluorescent probe. Microarrays are then hybridized 
with this labeled cDNA and analyzed by a scanning-laser microscope and 
computer programs. DNA microarrays have revolutioned the way in which gene 
expression can now be analyzed. The disadvantage is that it is very difficult to 
completely control all variables and individual genetic variation. Developing 
sophisticated algorithms and software tools to analyze data of this scale is also a 
challenge (Lockhart and Winzeler, 2000). 
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3. The early secretory pathway        
3.1 Structure and function of the endoplasmic reticulum 
The endoplasmic reticulum (ER) consists of a dynamic lipid bilayer and proteins 
spanning or attached to its membrane or residing in the lumen. The ER is 
organized into interconnected tubules and sacks extending through the cytosol 
(Adelman et al., 1973; Borgese et al., 1974; Lee and Chen, 1988). It is a single 
membrane system with a continuous intralumenal space, the ER lumen (Terasaki 
and Jaffe, 1991; Terasaki et al., 1994). The ER has many different functions, and 
consists of several morphologically and functionally distinct subcompartments: 
the rough ER, the smooth ER, the nuclear envelope and sections that contact 
other cellular organelles (Fig. 3) (Sitia and Meldolesi, 1992; Voeltz et al., 2002).  
 
 
Figure 3. Subcompartments of the ER: rough ER, smooth ER, nuclear envelope 
and a section in close contact with a mitochondrion. 
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3.1.1 The rough ER 
The rough ER (RER) is coated by membrane-bound ribosomes (Fig. 3) (Baumann 
and Walz, 2001). It has a central role in protein biosynthesis since all proteins 
destined for the secretory pathway are synthesized on the ribosomes attached to 
the ER (Wilkinson et al., 1997; Kalies and Hartmann, 1998) (Fig. 4). These 
ribosomes synthesize three types of proteins which all contain an ER signal 
sequence; soluble secretory proteins as well as transmembrane and soluble 
proteins destined for different compartments of the secretory pathway. Soluble 
proteins are translocated into the ER lumen (Fig. 4). The hydrophobic parts of 
transmembrane proteins span the ER membrane whereas hydrophilic tails and 
loops are oriented in the cytoplasm or in the ER lumen (Fig. 4) (von Heijne, 
1996). During and after translation proteins fold into their final three 
dimensional shape with the aid of chaperone proteins (Hartl, 1996; Bukau and 
Horwich, 1998) (Fig. 4). The folding information is included in an amino acid 
sequence of a polypeptide and proper folding is essential for the function of the 
protein. Proteins that are misfolded in the ER are retained until they reach their 
native conformation or are retrotranslocated back into the cytosol for 
degradation by the 26S proteasomes (Sherman and Goldberg, 1996). The 
unfolded protein response (UPR), comprising a group of highly specific signalling 
pathways, is activated upon accumulation of unfolded proteins in the ER lumen 
to ensure that protein folding capacity of the cell is not overwhelmed (Sidrauski 
et al., 1998).  
 
 
 
 
 
 
 
 
 
 
 
38 
Figure 4. Schematic picture of transcription and translation of proteins destined 
for the secretory pathway. A mRNA molecule is produced by transcription, intron 
sequences are removed and both ends are modified in the nucleus. On a RER 
bound ribosome in the cytoplasm the information in mRNA molecule is read from 
one end to another and a protein is translated. In the ER, the protein is folded 
with the aid of chaperones.  
            
                
 
After translation and folding with the aid of chaperones, some proteins become 
modified by the enzymes in the ER lumen: the amino terminal ER signal sequence 
is cleaved, disulfide bridges are formed and glycosylation by the addition of a 
common N-linked oligosaccharide is initiated (Kornfeld and Kornfeld, 1985; 
Helenius and Aebi, 2001). Several types of lipid modifications of proteins have 
been characterized in the ER, such as addition of a glycosylphosphatidylinositol 
(GPI) anchor to the C-terminus of some membrane proteins destined for the 
plasma membrane (Ferguson, 1992). At the same time the C-terminal 
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transmembrane part of the protein is removed. Proteins attached to the plasma 
membrane by a GPI anchor can easily be released in response to different signals 
(Ferguson, 1992). In addition, soluble proteins can be anchored to the lipid 
bilayer by myristylation in the ER or by prenylation or palmitoylation in the ER or 
the cis Golgi (Casey, 1995; Morello and Bouvier, 1996).  
 
3.1.2 The smooth ER 
The regions of the ER that have no ribosomes attached are called the smooth ER 
(SER; Fig. 3) (Voeltz et al., 2002). SER has several different functions including 
mediation of protein export from the ER and import into the ER, regulation of 
cytosolic Ca2+ concentration, initiation of ER regulated apoptosis, lipid synthesis 
and assembly as well as detoxification of several organic chemicals by converting 
them to safer water-soluble products. In many cells SER is scanty or partly 
smooth, partly rough. Large areas of SER are abundant only in certain cell types, 
such as muscle cells, neurons and liver cells. Most membrane proteins are shared 
between SER and RER but some are only found in one of them, and it is not 
known how SER and RER maintain distinct protein compositions. In the laboratory 
SER and RER can be separated by centrifugation (De Duve, 1971; Pryme, 1986).  
 
Newly synthesized proteins destined for post-ER compartments of the secretory 
pathway are selectively separated from ER-resident proteins at ER export sites, 
which are localized in the SER. These ER export sites are highly enriched in coat 
protein (COP) II and COPI transport components, which mediate anterograde 
transport out of the ER and retrograde transport into the ER (Bannykh et al., 
1996). 
 
ER has a central role in the regulation of Ca2+ concentration in the cytosol 
(Pozzan et al., 1994; Meldolesi and Pozzan, 1998). Ca2+ ions are stored in an ER 
lumen, and released and taken up in response to external signals. The ER lumen 
contains high concentrations of Ca2+ binding proteins and Ca2+ whereas in the 
cytosol the Ca2+ concentration is normally low. In the SER membrane there are 
both Ca2+ channels that release Ca2+ to the cytoplasm and Ca2+-ATPase molecules 
that pump Ca2+ back to the ER lumen (Missiaen et al., 1991; Mikoshiba et al., 
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1993; Camacho and Lechleiter, 1995; Hendershot et al., 1995). An increase in 
cytoplasmic Ca2+ concentration has important roles in e.g. neuronal 
depolarization and muscle contraction (Meldolesi and Pozzan, 1998). 
 
In ER stress, the UPR signal transduction pathway is first activated (Sidrauski et 
al., 1998). If the damage to the ER is too great or if balance is not restored 
within a certain window of time, an apoptotic response is elicited (Patil and 
Walter, 2001). Emerging evidence shows that the ER regulates apoptosis by 
initiating cell death signals of its own and sensitizing mitochondria to a variety of 
extrinsic and intrinsic stimuli (Breckenridge et al., 2003). Ca2+ release from the 
ER has been implicated as a key signalling event in many apoptotic models and 
several ER proteins have been shown to influence apoptosis or function as 
caspase substrates that may regulate the execution phase of apoptosis 
(Breckenridge et al., 2003). Moreower, caspase-12, which localizes to the ER, is 
highly specific to insults that elicit ER stress and is not proteolytically activated 
by other death stimuli (Nakagawa et al., 2000). 
 
Almost all of the major classes of lipids, including phospholipids and cholesterol, 
are synthesized in the SER, where lipid bilayers are also assembled. Phospholipid 
synthesis is catalyzed by enzymes in the ER and takes place exclusively in the 
cytosolic leaflet of the SER membrane (Alberts et al., 2002). After synthesis, 
phospholipid translocation proteins flip some phospholipids to the lumenal 
leaflet, equilibrating phospholipids between the two leaflets. Ceramide is 
produced in the SER and exported to the Golgi where it serves as a precursor for 
the synthesis of glycosphingolipids and sphingomyelin (Sandhoff and Kolter, 
2003). Because other cellular organelles are unable to carry out lipid synthesis, 
lipids have to be exported from the ER. The mechanisms underlying lipid 
transport between cellular organelles are not well known. 
 
3.1.3 The nuclear envelope 
The nucleus is surrounded by the nuclear envelope, consisting of two sheets of 
membranes and a lumen between them (Fig. 3). The inner and outer sheets are 
connected only at nuclear pores, and the outer sheet is continuous with the 
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peripheral ER (Voeltz et al., 2002). The proteins within the inner membrane are 
synthesized in the RER of the outer nuclear membrane and enter the inner 
membrane by diffusion through the pore membrane (Soullam and Worman, 
1995). Inner-sheet proteins attach directly or indirectly to nuclear structures 
such as chromatide or the lamina and are likely to be responsible for establishing 
and maintaining nuclear envelope structure (Ellenberg et al., 1997; Rolls et al., 
1999; Dreger et al., 2001).  
 
3.1.4 Parts of the ER in contact with other organelles 
The ER is closely associated with essentially all other organelles in the cell, 
including peroxisomes, mitochondria, Golgi, lysosomes and the plasma 
membrane, and these contact areas can be considered as subcompartments of 
the ER (Fig. 3) (Staehelin, 1997). These contain specific protein pools as well as 
proteins found everywhere in the ER. For example, part of the ER, termed the 
mitochondria-associated membrane (MAM), can be isolated with mitochondria 
and is enriched in several enzymes involved in lipid synthesis, such as 
phosphatidylserine (PS) synthase (Voelker, 2000). Some of the PS, synthesized in 
the ER, is transferred to mitochondria where it is decarboxylated and then 
transported back to the ER. There are at least two explanations for why the ER is 
in close contact with other cell organelles; 1) all organelles need lipids produced 
in the ER and direct contact may allow their direct transfer and 2) involvement 
of specialized ER regions in calcium signalling (Rizzuto et al., 1998; Voeltz et al., 
2002). Protein components of ER subcompartments are not well known and 
identification of these proteins will give valuable information concerning 
specialized functions of the ER.  
           
3.2 Membrane traffic between ER, ERGIC and Golgi complex 
Newly synthesized proteins destined to post-ER compartments of the secretory 
pathway are selectively separated from ER-resident proteins at ER export sites, 
also called ER exit sites. These proteins are transported between the ER and the 
cis Golgi through the ERGIC (Saraste and Kuismanen, 1984), also termed vesicular 
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tubular clusters (VTC) (Hauri et al., 2000), but the mechanisms underlying this 
traffic are not known in detail. 
 
Anterograde vesicle transport from the ER to the Golgi has been shown to require 
COPII coatomer binding (Barlowe et al., 1994; Barlowe, 1998). COPII vesicles bud 
from ribosome-free ER export sites which are randomly dispersed throughout the 
ER network. The COPII coat is composed of a small GTPase Sar1 and two large 
protein complexes Sec23/24 and Sec13/31 (Barlowe et al., 1994). However, 
there is also evidence that COPII is not required in the biogenesis of transport 
vesicles but instead acts in the generation and maintenance of the export domain 
of the ER (Mironov et al., 2003). Several types of amino acid motifs for type I 
membrane proteins are known to function as ER export signals and are 
recognized by the COPII complex: C-terminal diacidic DXE-containing motif 
(Aridor et al., 2001; Stockklausner et al., 2001) and C-terminal diphenylalanine 
(FF) motif (Fiedler et al., 1996; Stockklausner et al., 2001), which can be 
functionally substituted by a single phenylalanine or tyrosine at position -2, two 
leucines or isoleucines at position -1 and -2 or a single valine at position -1 (Nufer 
et al., 2002). In addition, dibasic motif, RK(X)RK, is known to function as an ER 
export signal for several type II membrane proteins (Giraudo and Maccioni, 
2003).  
 
ERGIC consists of clusters of vesicles and interconnected tubules. After budding 
from the ER exit sites, COPII vesicles lose their COPII coat and fuse with each 
other forming the ERGIC (Bannykh et al., 1998; Hauri et al., 2000). Another 
possibility is that uncoated vesicles fuse with a pre-existing ERGIC (Stephens and 
Pepperkok, 2001). It is still unclear whether ERGIC represents a transient 
transport intermediate that is constantly forming from the ER and consumed at 
the cis Golgi pole, or a more stable compartment shuttling back and forth 
between the ER and Golgi. 
 
Retrograde transport from Golgi to the ER and from ERGIC to the ER requires 
coat protein I (COPI) (Cosson and Letourneur, 1997). COPI coats contain small 
GTPase ARF and a pre-assembled coatomer complex of seven subunits (Rothman, 
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1994). ER-resident proteins are transported back to the ER in COPI coated 
vesicles which are formed in the ERGIC and in the cis Golgi. Several types of ER 
retention motifs, which are recognized by COPI, are known. Transmembrane ER-
resident proteins contain a cytoplasmic C-terminal dilysine ER retention motif 
K(X)KXX which have been shown to directly bind COPI (Jackson et al., 1990; 
Cosson and Letourneur, 1994; Letourneur et al., 1994). At least one ER retention 
motif, KDEL, which interacts directly with a KDEL receptor, has been 
characterized for soluble ER-resident proteins (Lewis and Pelham, 1990; Semenza 
et al., 1990). This receptor-ligand complex is recognized by COPI and the ligand 
is transported back to the ER in COPI coated vesicles. In addition, a COPI 
independent pathway from Golgi to the ER has been described (Girod et al., 
1999; White et al., 1999). Both COPI and COPII vesicles move along microtubular 
networks and targeting of the vesicles to organelle membranes is defined by 
SNARE-complexes (Sogaard et al., 1994; Bednarek et al., 1995; Scales et al., 
1997). 
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Aims 
 
The specific aims of this study were: 
1. to identify and characterize the CLN8 gene underlying EPMR 
2. to characterize wild-type and mutant CLN8 proteins and their 
intracellular localization in non-neuronal and neuronal cells 
3. to identify the orthologous mouse Cln8 gene, and to characterize the 
spatial and temporal expression of Cln8 in different developmental 
stages and in the mouse hippocampal kindling model of epilepsy 
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Materials and methods 
 
EPMR patients 
Twenty-two EPMR patients, 10 carrier parents and 28 healthy siblings, originating 
from the Kainuu region, were included in this study. All patients were distantly 
related to one another and they all were diagnosed by Dr. Aune Hirvasniemi. The 
genealogical data have been earlier described (Hirvasniemi et al., 1994). Control 
samples were taken from 271 unrelated Finnish individuals, 92 individuals 
originating from the high incidence area of Kainuu region, and 70 individuals of 
non-Finnish origin. 
 
Studies including patients (I) have been approved by the Ethics Committee of the 
Department of Medical Genetics, University of Helsinki. Patients were included in 
the study with the permission of their guardians. Healthy siblings were not 
informed whether they are carriers or not. Animal experiments in publication III 
have been approved by the Animal Care and Use Committee of the National 
Public Health Institute. mRNA in situ hybridization experiments with healthy 
mice (IV) were conducted according to the “European Convention for the 
Protection of Vertebrate Animals used for Experimental and other Scientific 
purposes” with the approval of the local ethics committee. All kindling 
experimental procedures (IV) were performed according to the National Institute 
of Health Guide for the Care and Use of Laboratory Animals and approved by the 
local ethics committee. All measures were taken to minimize the number and 
suffering of the animals used.   
 
The details of the experimental methods used in this study are described in the 
original publications (I-IV) according to the table below.  
 
Table 5. Methods used in this study  
Methods Original publication 
Recombinant DNA techniques (cloning) II, III, IV 
Polymerase chain reaction (PCR) I, II, III, IV 
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Methods Original publication 
Reverse-transcriptase PCR (RT-PCR) I, IV 
Quantitative real-time RT-PCR IV 
Semiquantitative PCR IV 
DNA extraction I, II, III 
DNA sequencing I, II, III, IV 
cDNA cloning using rapid amplification of cDNA ends (RACE) method I 
Site-directed mutagenesis II, III 
Patient mutation analysis I 
RNA extraction I, IV 
Detection of RNA by In situ hybridization analysis IV 
Detection of RNA by Northern-blot analysis I, IV 
SDS-PAGE II, III 
Enhanced chemiluminiscence (ECL) II, III 
Protein detection by Western blot analysis II, III 
Protein detection by pulse labeling analysis II 
Protein purification by immunoprecipitation  II 
Cell culture II, III 
Preparing of mouse hippocampal primary neurons III 
Tissue fractionation III 
Transient transfection II, III 
Raising of antibodies II 
Serum antibody purification III 
Raising of recombinant Semliki Forest viruses and infection III 
Immunofluorescence staining II, III 
Confocal and fluorescence microscopy II, III 
Database and computer analysis I, II, III, IV 
Statistical analysis IV 
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Results and discussion 
1. Identification and characterization of human CLN8 and mouse 
Cln8 genes (I, unpublished) 
1.1 Identification of the human CLN8 gene 
The CLN8 gene was identified using a positional cloning strategy. Linkage and 
haplotype analysis, genetic and physical mapping of the EPMR locus and 
construction of yeast artificial chromosome (YAC) and bacterial artificial 
chromosome (BAC) contigs across the EPMR region have been described earlier 
(Tahvanainen et al., 1994; Ranta et al., 1996; Ranta et al., 1997). A 650 bp novel 
transcript, LS136B11, was identified by a cDNA selection strategy and YAC clones 
spanning the CLN8 region. LS136B11 was extended by cDNA library screening and 
a cDNA cloning using the RACE method. This resulted in a 4819 bp sequence 
which includes an open reading frame (ORF) of 861 bp encoding a putative 
transmembrane protein of 286 aa. This CLN8 gene consists of three exons, the 
first of which is not translated (Fig. 5). The exact sizes of exons one and three 
are unknown. The 3´untranslated region (UTR) contains at least four poly(A) 
signals at 1296 bp, 3231 bp, 3278 bp and 4820 bp (Fig. 5). The size of the intron 
between exons 1 and 2 is 7046 bp and the size of the intron between exons 2 and 
3 is 8652 bp (http://www.ensembl.org/).  
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Figure 5. Genomic structure of the CLN8 gene. The three exons of CLN8 are 
shown to scale as boxes. The coding region, shown in black, is divided into exons 
two and three. The introns (7046 bp and 8652 bp) are depicted as lines between 
exons and are not drawn to scale. The 3´UTR contains at least four polyA signals 
(A), the base pair positions of which are shown. The exact sizes of exons one and 
three are unknown.  
 
 
 
1.2 Tissue expression analysis of the CLN8 gene 
Expression of the CLN8 gene was characterized by Northern blot analysis and RT-
PCR. In a human multiple tissue Northern blot, including RNA from 8 different 
adult tissues, 1.4, 3.4 and 7.5 kb CLN8-specific transcripts were detected in all 
tissue samples (I, Fig. 2). The 1.4 kb band most likely corresponds to the poly(A) 
site at 1296 bp and the 3.4 kb band corresponds most likely to the poly(A) sites 
at 3231 bp and 3278 bp (Fig. 4). A transcript corresponding to the poly(A) site at 
4820 bp was not detected in Northern blot analysis. The 7.5 kb transcript 
detected in the Northern blot is likely to represent a transcript deriving from the 
unknown part of the 3´UTR. However, because the exact sizes of exon 1 and 
exon 3 are unknown, these suggestions are preliminary and should be re-
considered after identification of the complete CLN8  5´UTR and 3´UTR 
sequences.  
 
RT-PCR analysis covering the 861 bp open reading frame (ORF) of CLN8 resulted 
in a single fragment of the same size in all samples from human cerebellum, 
placenta, and fibroblasts, suggesting that the different transcripts detected in 
the Northern blot analysis are most likely due to alternative poly(A) signals in the 
3´UTR rather than alternative splicing in the coding region. It is, however, not 
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excluded that the CLN8 gene has several transcription initiation sites. RT-PCR 
analysis of lymphoblastoid RNA from EPMR patients, carriers and controls 
resulted in the expected size fragment in each case, indicating that the patient 
mutation (see below) does not affect splicing of CLN8 mRNA.  
 
1.3 Mutation analysis in EPMR 
The coding region of CLN8 was screened for mutations in EPMR patients and their 
family members. One missense mutation (c.70C>G) was found to be homozygous 
in all 22 EPMR patients, whereas all 10 carrier parents and 19 of 28 healthy 
siblings were heterozygous carriers (I, Fig 3). None of the 433 healthy Finnish and 
non-Finnish control individuals were homozygous for c.70C>G. A carrier 
frequency of 1:135 was observed in Finland and 1:46 in the Kainuu region. In 
another study, no carriers were found in 597 healthy individuals from four 
different parts of Finland (Pastinen et al., 2001). These data suggest, together 
with known population history and geographical distribution of EPMR families, 
that EPMR is caused by a single founder mutation. The c.70C>G mutation results 
in an arginine to glycine substitution at codon 24 (R24G) in the CLN8 polypeptide. 
This arginine is located at the border of the first predicted transmembrane 
domain (see below) but the hydrophobicity prediction is not significantly changed 
when it is replaced by glycine. However, the R24G mutation could result in 
translocation of the CLN8 polypeptide "inside-out" in the membrane or in some 
other way affect the function of CLN8. In addition to the c.70C>G, two 
polymorphisms were found in the CLN8 gene; one silent (c.507T>C) and one 
missense [c.464T>C, (V155A)] variant (I). Three new likely polymorphisms, not 
segregating with EPMR phenotype, were identified later, one silent (c.90C>T) and 
two missense [c.674A>G (N225S) and c.722T>G (L241R)] variants (unpublished). 
Recently, four different mutations in the CLN8 gene have been identified in 
variant late infantile onset NCL in a subset of patients of Turkish origin, further 
proof of the connection between CLN8 and the NCL phenotype in human (Ranta 
et al., 2004).  
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1.4 Characterization of the mouse Cln8 gene 
In BLAST comparisons of CLN8 against databases of various species several 
orthologous mouse expressed sequence tags (ESTs) were identified and the 
mouse Cln8 sequence, including an ORF of 867 bp, was assembled. The ORF of 
mouse Cln8 is 82% identical to human CLN8 and the proteins are 85% identical at 
amino acid level (I, Fig. 4). The hydrophobicity predictions of human and mouse 
CLN8 proteins were almost identical, suggesting that the mouse Cln8 protein is 
also a transmembrane protein with several transmembrane domains. 
1.5  Mutation analysis in the mnd mouse 
Cln8 was located on mouse chromosome 8 in the same region where the mutation 
underlying the mnd mouse, a naturally occuring mouse model for NCL, had been 
localized (Messer and Flaherty, 1986; Messer et al., 1987). A homozygous 
insertion (c.267-268insC) in Cln8, resulting in a frameshift and predicting a 
truncated protein, was found in mnd mice but not detected in wild-type (wt) 
mice or the mouse Cln8 gene sequence assembled from EST clones (I, Fig. 5). 
This result further confirmed that the CLN8 gene underlies EPMR and indicated 
that mnd and EPMR are caused by mutations in orthlogous genes.  
 
There are several differences between the clinical features of EPMR and mnd. 
Epilepsy, the first and hallmark symptom of EPMR, is not a prominent feature in 
mnd (Messer and Flaherty, 1986; Hirvasniemi et al., 1994). Whether mnd mice 
exhibit epileptic seizures at all should be confirmed by electroencephalogram 
(EEG) recordings. Moreover, retinal degeneration and severe paralysis observed 
in mnd, have not been reported in EPMR (Messer and Flaherty, 1986). However, 
some EPMR patients have decreased visual acuity (Hirvasniemi et al., 1995). 
These phenotypic differences may reflect the severity of different mutations in 
orthologous CLN8 genes. The mnd mutation resulting in a truncated protein is 
likely to be more severe than a missense mutation underlying EPMR.  Such 
phenotypic differences are also seen in human patients with a CLN8 defect 
leading to at least two different NCL phenotypes in humans, EPMR in Finnish 
patients and variant late infantile NCL in several Turkish patients (Ranta et al., 
2004). Mutations in orthologous genes can lead to different disease phenotypes in 
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different species due to their different genetic background. For example, 
mutations in myosin IIIA lead to progressive nonsyndronic hearing loss in humans 
but progressive retinal degeneration in D. melanogaster (Walsh et al., 2002), and 
mutations in the PAX3 gene lead to Waardenburg syndrome with deafness in 
humans and to Splotch phenotype with no signs of auditory defects in mice 
(Moase and Trasler, 1989; Steel and Smith, 1992). Even the different genetic 
background within one species can affect the disease phenotype markedly. This 
is true in mnd mice, in which the age of onset is earlier and speed of progression 
faster in an AKR background than in a C57Bl/6J background (Messer et al., 1995; 
Messer et al., 1999). 
 
2. Intracellular localization of wild-type and mutated CLN8 
proteins in non-neuronal cells (I, II, III, unpublished) 
2.1 Characterization of the CLN8 protein 
The CLN8 gene encodes a novel protein of 286 aa with a predicted molecular 
weight of approximately 33 kDa. Several computer-based prediction programs 
have been developed for prediction of transmembrane domains directly from 
amino acid sequence (Moller et al., 2001). These predictions are often based on 
hydrophobicity blots (Kyte and Doolittle, 1982). The Kyte and Doolittle 
hydrophobicity plot of the CLN8 polypeptide reveals four separate hydrophobic 
regions and one relatively long hydrophobic stretch between approximately aa 
107-182. Based on seven different computer program predictions, the CLN8 
protein is likely to be a transmembrane protein with 4-7 transmembrane domains 
(Table 6, unpublished). Variation in these predictions is most likely due to the 
long hydrophobic stretch in the middle of the CLN8 polypeptide. The N-terminal 
tail most likely consists of at least 18 amino acids and the C-terminal tail at least 
36 amino acids as predicted by all programs (Table 6). Transmembrane domains 4 
and 5, predicted by all programs except PredictProtein, are likely to exist, 
whereas the existence of transmembrane domains  2, 3 and 6 is unclear.  
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Table 6. Computer program-based predictions of transmembrane (TM) domains of 
CLN8.  
TM 
domain 
TopPred2 TMpred TMHMM SOSUI HMMTOP Predict 
Protein 
estimated 
reliability 
1. 
 
24-25 23-43 19-41 24-46 16-40 26-44 +++ 
2. 
 
71-91 66-87 - - 71-91 67-84  
3. 
 
100-120 105-124 102-124 - 107-127 110-134 + 
4. 
 
133-153 133-156 133-151 134-156 133-153 - ++ 
5. 
 
160-180 151-180 158-180 159-181 159-179 160-177 ++ 
6. 
 
200-220 - 195-216 - 195-215 206-223  
7. 
 
228-248 231-248 223-245 228-250 231-250 230-247 +++ 
 
In order to detect the size and intracellular localization of the CLN8 protein, 
several antibodies against selected CLN8 peptides were generated. These peptide 
sequences were located in putative hydrophilic tails or loops in the CLN8 
polypeptide chain, but since the topology of CLN8 remains undefined, raising 
anti-peptide antibodies had to rely on predictions about its topology. So far only 
one antibody, 391/CLN8, recognizes overexpressed CLN8 protein in 
immunofluorescence and Western blot analysis. In addition, the affinity-purified 
391/CLN8 antibody is sensitive enough to detect endogenous Cln8 by Western 
blot analysis. Unfortunately, 391/CLN8 does not immunoprecipitate CLN8. 
Intensive efforts, and also some good luck, will be needed in the future to 
generate an antibody that detects endogenous CLN8. Another approach was to 
add a FLAG epitope tag to the CLN8 polypeptide and detect the protein with an 
anti-FLAG antibody. It has been confirmed, by compairing wtCLN8 and 
wtCLN8+FLAG proteins in puls-chase and immunofluorescence analysis, that the 
FLAG epitope itself is unlikely to change the size or localization of the protein 
within the cell.   
 
To characterize the size of CLN8 in living cells, the coding region of CLN8 cDNA 
was cloned into an SvPoly expression vector (SvPoly-CLN8). COS-1 cells were 
transiently transfected with SvPoly-CLN8 expression vector and the expressed 
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polypeptide was analyzed using Western blot and the CLN8 specific peptide 
antibody 391/CLN8. Compatible with predictions, one approximately 33 kDa band 
was detected (II, Fig. 1A). 
 
To detect possible proteolytic processing of CLN8, CLN8 polypeptide containing a 
N-terminal FLAG epitope was expressed and analyzed in COS-1 cells using pulse-
chase and immunoprecipitation methods. Since the 391/CLN8 antibody does not 
immunoprecipitate CLN8, an antibody against the FLAG epitope was used to 
immunoprecipitate the CLN8-FLAG polypeptide. The size of CLN8+FLAG 
corresponded approximately to the wild-type CLN8 in every chase, indicating 
that CLN8 polypeptide is not processed during its maturation (II, Fig. 1B). 
Treatment with endoglycosidase H did not affect the size of CLN8+FLAG, 
suggesting that N-glycosylation is unlikely to occur in the CLN8 polypeptide (II, 
Fig. 1B).  
 
2.2 Intracellular localization of the wtCLN8 protein in non-neuronal cells 
Towards understanding the normal and disturbed metabolism of the CLN8 
protein, the intracellular localization of CLN8 was first characterized in non-
neuronal cells using indirect immunofluorescence analysis and confocal 
microscopy. A stably transfected CHO-CLN8 cell line as well as transiently 
transfected BHK and HeLa cells were labeled with 391/CLN8 peptide antibody 
and several different antibodies against subcellular marker proteins. CLN8 
immunostaining revealed a reticular staining pattern typical for ER. Strong co-
localization of CLN8 with ER marker protein PDI as was partial co-localization 
with ERGIC marker ERGIC-53 was observed (II, Fig. 2). No notable co-localization 
of CLN8 with Golgi or late endosomes/lysosomes was seen (II, Fig. 2). Like ERGIC-
53 (Tang et al., 1995), CLN8 was concentrated in the ERGIC when cells were 
incubated at 15°C and moved back to the ER when the 15°C heating block was 
released (unpublished). These findings imply that the CLN8 protein is an ER-
resident protein which partially localizes to the ERGIC (Fig 6).  
 
Interestingly, another NCL protein, CLN6, has recently been shown to be an ER-
resident transmembrane protein with seven predicted transmembrane domains 
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(Fig. 5). Mutations in the CLN6 gene underlie vLINCL in humans and nclf in mice 
(Gao et al., 2002; Wheeler et al., 2002). Defects in the CLN6 protein have been 
shown to lead to lysosomal dysfunctions (See also sections 1.3 and 1.4)  (Heine et 
al., 2004). 
 
2.3 Analysis of the putative ER retention signal KKRP 
To analyze the putative recycling of CLN8 between the ER and ERGIC, potential 
transport and retention signals from the CLN8 aa sequence were sought. The 
CLN8 polypeptide was found to contain an ER retention signal KKRP in the C-
terminus (aa 283-286) but no other transport or retention signals were found. 
The two lysines in the C-terminal KKXX motif are known to be critical for coat 
protein 1 (COP-1) binding and for Golgi-to-ER retrieval (Cosson and Letourneur, 
1994; Letourneur et al., 1994; Andersson et al., 1999). To determine if the KKRP 
motif in CLN8 is functional, BHK cells were transiently transfected with two 
different expression vectors containing mutant CLN8 polypeptides; in the first 
both lysines in the KKRP motif were replaced with arginines (K283R/K284R) and 
in the second the first lysine in the KKRP motif was replaced with serine (K283S). 
The localization of these mutant CLN8 proteins was determined by 
immunofluorescence analysis and confocal microscopy. The CLN8(K283R/K284R) 
polypeptide co-localized fully with Golgi marker protein CTR433 and the 
CLN8(K283S) polypeptide co-localized partially with CTR433 and partially with ER 
marker protein PDI, indicating that both lysines in the KKRP motif are needed for 
ER retention (II, Fig. 3). These data strongly suggest that the KKRP motif in the 
CLN8 polypeptide functions as an ER retrieval signal and that CLN8 is an ER-
resident protein that recycles between ER and ERGIC. The CLN8 polypeptide does 
not contain known ER export signals: C-terminal diacidic DXE-containing motif 
(Aridor et al., 2001; Stockklausner et al., 2001), C-terminal diphenylalanine (FF) 
motif (Stockklausner et al., 2001; Nufer et al., 2002) or its substituents (Nufer et 
al., 2002) or dibasic ER export motif RK(X)RK (Giraudo and Maccioni, 2003). 
Whether CLN8 is actively transported or passively leaking out of the ER remains 
to be determined.  
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Numerous putative functions for the ER-resident CLN8 protein can be proposed. 
It could aid translocation or dislocation of other proteins across the ER 
membrane as well as folding, assembling and targeting of proteins destined to 
other cellular compartments. With several transmembrane domains CLN8 could 
also form a channel and have a role in the transfer of other proteins or ions 
through the ER membrane. In addition, it could function in the ER exit sites and 
mediate the secretion of proteins from the ER. Based on sequence homology 
searches, CLN8 has recently been linked to a TLC (TRAM, Lag1 and CLN8) 
superfamily of proteins proposed to have a role in biosynthesis, metabolism and 
sensing of lipids (Winter and Ponting, 2002). The hypothesis that CLN8 is involved 
in lipid metabolism is highly interesting and should be further investigated. It is 
known that CLN8 does not reconstitute Acyl-CoA-dependent ceramide synthesis 
in yeast but no other studies on the possible function of CLN8 in lipid metabolism 
have been reported (Guillas et al., 2003). CLN8 does not have significant 
homology with other protein families. 
 
2.4 Intracellular localization of mutant human CLN8 polypeptides 
representing patient mutations and mnd mutation in non-neuronal cells 
The localization of four mutant CLN8 proteins, representing the ERMR missense 
mutation CLN8(R24G) found in all Finnish EPMR patients, two missense mutations 
CLN8(R204C) and CLN8(W263C) found in a subset of Turkish patients with variant 
late infantile onset NCL (Ranta et al., 2004) and the mnd truncating mutation 
(c.267-268insC), was determined using transiently transfected BHK cells, 
immunofluorescence analysis and confocal microscopy. Because the 391/CLN8 
antibody recognizes the C-terminal part of CLN8 and the truncated CLN8 protein 
representing the mnd mutation lacks the C-terminus, a FLAG epitope tag was 
added to the c-terminus of this polypeptide [CLN8(c.267-268insC)-FLAG] and it 
was detected using an antibody against the FLAG epitope. The CLN8(R24G), 
CLN8(R204C) and CLN8(W263C) proteins localized to the ER and partially to the 
ERGIC, indicating that these patient mutations do not result in disturbed 
recycling of CLN8 (II, Fig. 4; III, Fig. 4). The CLN8(c.267-268insC)-FLAG protein 
localized fully in the ER, suggesting that the truncated protein is most likely 
unfunctional and unable to traffic between the ER and ERGIC (II, Fig. 4). 
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Figure 6. Localization of NCL proteins, including CLN8, in different compartments 
of the secretory pathway in non-neuronal cells. 
 
 
 
 
3. Intracellular localization of wild-type and mutated CLN8 
proteins in neuronal cells (III) 
3.1 Intracellular localization of the wtCLN8 protein in neuronal cells 
Because the most severe damage in EPMR involves the central nervous system 
(CNS) and in particular the hippocampal sectors CA2-CA4 (Herva et al., 2000), 
the localization of CLN8 was next characterized in mouse hippocampal primary 
neurons. As no antibodies detected endogenous human or mouse CLN8 protein in 
immunofluorescence or immunoelectron microscopy, one had to rely on analysis 
of exogenously expressed recombinant CLN8 in the localization studies. The 
distribution of the CLN8 protein in fully matured mouse hippocampal primary 
cells was analyzed using Semliki Forest Virus (SFV)-mediated expression of CLN8 
(wtCLN8-SFV), immunofluorescence analysis and conventional fluorescence 
microscopy. Infected hippocampal neurons were double immunofluorescence 
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stained with polyclonal 391/CLN8 antibody and two monoclonal antibodies 
against intracellular marker proteins, PDI for ER and CTR433 for Golgi. CLN8 
staining co-localized clearly with PDI staining indicating that CLN8 is localized in 
the ER (III, Fig 1A). However, higher magnification of neuronal cell soma showed 
that CLN8 immunostaining may extend closer to the plasma membrane than PDI 
(III, Fig 1B). Double immunofluorescence staining of PDI with another polyclonal 
ER marker protein calnexin showed full co-localization, thus further confirming 
the ER localization of CLN8, and emphasizing slight localization differences 
between ER proteins (III, Fig. 1A). No notable co-localization with Golgi marker 
protein CTR433 was observed (III, Fig. 1B).  
 
Calnexin is an ER-resident type I transmembrane protein with one membrane 
spanning region (Fig. 5). Calnexin is an ER-specific lectin with specificity for 
terminal glucose residues on high mannose N-linked glycans and functions as an 
ER chaperone (Hammond et al., 1994). The so-called calnexin cycle is central to 
the quality control system, which ensures proper folding of proteins before 
export from the ER (Zapun et al., 1999). Binding by calnexin or another ER 
lectin, calreticulin, retains unfolded glycoprotein in the ER permitting foldases to 
facilitate folding of the protein into the correct 3-D arrangement. The calnexin 
cycle allows multiple folding cycles before a misfolded protein is targeted for 
degradation. This ensures that only properly folded glycoproteins leave the ER 
(Parodi, 2000). No disease-causing mutations in the gene encoding calnexin have 
been found. It remains to be seen whether CLN8 would have a role, like calnexin, 
in protein folding and quality control. 
 
Another example of ER membrane proteins, associated with neurodegeneration, 
is presenilin-1 (PS1). PS1 is a transmembrane protein with 6-8 predicted 
transmembrane regions (Doan et al., 1996; Dewji and Singer, 1997; Lehmann et 
al., 1997; Nakai et al., 1999; Dewji et al., 2004). Similar to CLN8, it localizes to 
the ER and the ER-Golgi intermediate compartment (ERGIC) in non-neuronal 
cells, while in neuronal cells PS1 resides in a novel axonal compartment outside 
the ER and ERGIC (Walter et al., 1996; Annaert et al., 1999; Kamal et al., 2001). 
PS1 has a γ-secretase activity important for the proteolytic processing of several 
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proteins, including amyloid precursor protein (APP) (Wolfe, 2002; Li et al., 2003). 
In addition, PS1 interacts with proteins involved in neuronal cell adhesion and 
apoptosis (Passer et al., 1999; Annaert et al., 2001). Mutations in the presenilin-
1 gene lead to pathogenesis of early-onset Alzheimer´s disease (St George-
Hyslop, 2000). 
 
3.2 Polarized targeting of CLN8 
The localization of CLN8 in neuronal extensions indicated possible polarized 
targeting for CLN8. To test possible polarization, CLN8 was first expressed in 
polarized and non-polarized epithelial CaCo-2 cells using SFV-mediated 
expression of His-tagged CLN8 (wtCLN8-His-SFV). Cells were immunostained with 
391/CLN8 antibody and antibodies against subcellular marker proteins PDI and 
calnexin for ER and ERGIC-53 for ERGIC. Apically targeted 
aspartylglucosaminidase protein (AGA) and basolaterally targeted PPT1 protein 
were expressed as controls in polarized CaCo-2 cells. Similarly to other non-
neuronal cells, CLN8 was detected in the ER and partially in the ERGIC in non-
polarized CaCo-2 cells (III, Fig. 2A). However, in polarized CaCo-2 cells CLN8 
showed basolateral targeting (III, Fig. 2B), while staining of ER marker proteins 
PDI and calnexin did not demonstrate polarized localization indicating that the 
ER is not polarized in these cells (III, Fig. 2B). The possible polarization of CLN8 
in mouse hippocampal neurons was analyzed by comparing CLN8 staining with 
axonal MAP1 and dendritic MAP2 markers. Of the NCL proteins, PPT1 is axonally 
targeted and CLN3 co-localizes with axonal markers (Luiro et al., 2001; Ahtiainen 
et al., 2003). In contrast to PPT1 and CLN3, CLN8 was not differentially 
distributed between axons and dendrites indicating that in neurons CLN8 is not 
polarized. 
 
The plasma membrane of epithelial cells is divided into apical, basal and lateral 
domains, which have distinct protein and lipid composition. This asymmetric 
distribution of cell surface molecules is essential for the normal functions of 
epithelial cells (Caplan, 1997). The apical pole of epithelial cells is usually in 
contact with the external surface of an organism, such as the lumenal contents 
of the intestine. The basal surface lies on a basement membrane and is in closest 
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proximity to blood vessels and capillaries, whereas the lateral surface is adjacent 
to other cells in the same epithelium and often contains specialized junctional 
domains that allow interactions among adjacent cells in the same epithelium 
(Brown and Orci, 1988). Newly synthesized transmembrane proteins can be 
delivered apically, basolaterally or to both poles of an epithelial cell. These 
proteins usually contain specific transport signals in their cytoplasmic domains. 
For example, tyrosine-based signals (YXXØ), which were first identified on 
proteins that are internalized by clathrin-coated pits, are known to direct 
basolateral targeting (Chen et al., 1990; Collawn et al., 1990). Another amino 
acid motif that serves a similar function is the dileucine (LL) motif found in the 
cytoplasmic tails of several proteins (Birnbaumer et al., 1992; Verhey and 
Birnbaum, 1994). However, many basolaterally targeted proteins, including 
CLN8, have no recognizable signals that direct this targeting. 
 
3.3 Localization of Cln8 in mouse brain fractions 
Subcellular fractionation of mouse brains was used to analyze the localization of 
endogenous mouse Cln8 protein. The affinity-purified 391/CLN8 antibody was 
sensitive enough to detect endogenous Cln8 in Western blot analysis. Postnuclear 
supernatant of mouse brains was centrifuged and pellet (P) and supernatant (S) 
fractions collected after 10 000 x g (P1, S1) and 100 000 x g (P2, S2) 
centrifugations. Most of the Cln8 protein was detected in the S1 fraction, 
indicating that it is not likely to be enriched in the lysosomal or mitochondrial 
membranes (III, Fig. 3). After 100 000 x g centrifugation, the majority of the Cln8 
immunopositivity was detected in S2 and only a small portion in P2 fractions (III, 
Fig. 3). ER- and ERGIC-specific membrane proteins calnexin and p58 appeared in 
P1 and P2 fractions, showing that part of the brain-specific endogenous Cln8 
protein is not fractionated similarly with these proteins (III, Fig. 3). In addition, 
presynaptic synaptophysin (SYP), which appeared in P1 and P2 fractions, was 
fractionated differently from the Cln8 protein (III, Fig. 3).  
 
In addition to the ER-retention motif KKRP, CLN8 does not contain other evident 
transport signals, such as a PDZ domain ligand signal or signals that direct 
basolateral targeting as discussed earlier. PDZ domain-mediated protein-protein 
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interactions are known to achieve and maintain the proper targeting of signaling 
molecules in polarized cells (Bezprozvanny and Maximov, 2001). As CLN8 has not 
been seen to localize to Golgi or post-Golgi compartments, it is unlikely that it 
traffics further in the secretory pathway, and alternative mechanisms underlying 
its polarization in CaCo-2 cells must exist. One possibility is that CLN8 is 
transported outside the ER. Like several other ER-resident proteins, CLN8 could 
be involved in ER-mediated phagosytosis and located in phagosomes that bud 
from the ER and fuse with the plasma membrane to supply membrane for the 
formation of nascent phagosomes (Garin et al., 2001). 
 
Partially different subcellular localization was observed between Cln8 and other 
ER/ERGIC proteins in subcellular fractionation study of mouse brains. One 
possibility is that Cln8 could be distributed to a subcompartment of the ER in 
polarized cells. For example, a Ca2+ channel Inositol 1,4,5-triphosphate (IP3) 
receptor (IP3R), is concentrated in a subcompartment of the ER close to the tight 
junctions in polarized epithelial MDCK cells but co-localizes with ER markers in 
non-polarized MDCK cells (Colosetti et al., 2003). Moreover, like CLN8, InsP3R is 
associated with ER membranes and localizes evenly throughout the cytoplasm, 
comprising cell body, perinuclear area, axon, and dendrites in neuronal cells 
(Pozzan et al., 1994). IP3R is one of the key components in many important signal 
transduction and amplification pathways. It forms a homotetrameric Ca2+ channel 
in the ER membrane (Michikawa et al., 1994). The channel opens by binding of 
two co-agonists, IP3 and Ca2+, and releases Ca2+ from the ER lumen into the 
cytoplasm (Finch et al., 1991). This process is crucial for neuronal transmission 
and for many other functions that relate to morphological and physiological 
processes in living organisms, such as memory, learning, behavior, fertilization, 
cell proliferation, cell division and development (Berridge, 1998). In addition, 
IP3R signalling has an important role during the early steps of apoptosis. IP3R1-
deficient mice generally die in utero, while born animals have severe ataxia and 
tonic or tonic-clonic seizures and die by the weaning period (Matsumoto et al., 
1996). Electroencephalograms show that IP3R1 deficient mice suffer from 
epilepsy but light microscope observations show no abnormalities of the brain or 
peripheral tissues (Matsumoto et al., 1996). Mutations in IP3R genes have not 
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been found in human patients. Whether CLN8 resides in an ER subcompartment 
or traffics outside the ER remains to be determined by more accurate methods 
such as immunoelectron microscopy. 
 
3.4 Intracellular localization of mutant CLN8 proteins in neuronal cells 
The subcellular localizations of three mutant CLN8 polypeptides, representing 
patient mutations CLN8(R24G), CLN8(R204C) and CLN8(W263C), were analyzed by 
SFV-mediated expression in fully matured mouse hippocampal primary neurons. 
The subcellular localization of these mutant CLN8 proteins was similar to wild-
type CLN8 protein indicating that, like in non-neuronal cells, these disease 
mutations do not affect the intracellular localization of CLN8 (III, Fig 5 and 6).  
 
Based on the protein identification program PIX the topology of CLN8(R24G) and 
CLN8(W263C) seem to be almost identical with wtCLN8 whereas CLN8(R204C) 
may contain additional transmembrane domains. In addition, the arginine that is 
mutated to cysteine in R204C is extremely conserved among TLC proteins in all 
species (Winter and Ponting, 2002). However, all of these mutant proteins 
localized similarly to wtCLN8 in both non-neuronal and neuronal cells, indicating 
that the disease mutations do not cause mistargeting of CLN8. Thus the 
mutations most likely affect other functionally important domains of CLN8 and 
result in unfunctional protein or protein with reduced activity or altered 
function. The phenotype of Finnish EPMR patients, caused by the R24G mutation 
in CLN8, is clearly distinct from the more severe phenotype of variant late 
infantile onset NCL, in which several different mutations have been identified 
including R204C and W263C, in a subset of Turkish patients. However, this 
genotype-phenotype correlation can not be detected at the level of protein 
localization, suggesting that this correlation most likely exists at the level of 
protein functioning.  
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4. Expression analysis of the Cln8 gene (IV) 
4.1 Northern  blot analysis of Cln8 
The expression of Cln8 was first analyzed by Northern blotting in nine different 
adult mouse tissues and in 14-day-old mouse whole embryos. One approximately 
3 kb Cln8-specific transcript was detected in all tissues (IV, Fig. 1A). In addition, 
one ~7 kb transcript was detected in all tissues except testis and heart and one 
~2 kb transcript was detected in spleen (IV, Fig. 1A). The number and sizes of 
Cln8 transcripts resemble those of human CLN8, which produces transcripts of 
1.4 kb, 3.4 kb and 7.5 kb in all tissues studied (I, Fig. 2). Contrary to human 
CLN8, all Cln8 transcripts were not detected in every tissue. In both mouse Cln8 
and human CLN8 RT-PCR analysis covering the ORF resulted in a single fragment 
in all tissues suggesting that the different size transcripts are due to alternative 
3´UTRs rather than alternative splicing of the protein coding region. It is also 
possible that CLN8/Cln8 genes have several transcription initiation sites.  
 
4.2 Semiquantitative and real-time quantitative RT-PCR analysis of Cln8 
Next, the expression level of Cln8 was analyzed by semiquantitative PCR and 
quantitative real-time RT-PCR analysis in eight different adult mouse tissues and 
7-day, 11-day, 15-day and 17-day-old whole mouse embryos. Both analyses 
confirmed that Cln8 is ubiquitously expressed in mouse tissues (IV, Fig. 1B and 
1C). Semiquantitative PCR analysis indicated low-to-medium abundance of Cln8 
mRNA in all tissues (IV, Fig. 1B). Quantitative analysis showed highest expression 
of Cln8 in adult liver and spleen, 2.5 and 2.2 fold higher than in the brain, and 
lowest expression in adult lung and testis and 11-day embryo, 0.5, 0.03 and 0.6 
fold lower than in the brain (Fig. 7; IV, Fig. 1C). This indicates that the 
expression levels of Cln8 in adult mouse tissues as well as in whole mouse 
embryos do not differ dramatically. Very low expression of Cln8 in testis could 
reflect a high level of the analyzed control gene in this tissue.  
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Figure 7. Real-time quantitative RT-PCR analysis of Cln8 expression in mouse 
tissues. Expression of Cln8 in brain, which was given a value of 1, was used as 
control. Expression of Cln8 in other tissues is shown as a fold of control.  
 
              
 
 Both human and mouse CLN8 are ubiquitously expressed and the storage 
material in both human patients and mnd mice accumulates in all tissues. 
However, the most prominent damage in EPMR involves central nervous system, 
especially the third layer of the isocortex and hippocampal regions CA2-CA4 
(Herva et al., 2000). In mnd the brain remains relatively intact but the motor 
neurons are severely affected (Bronson et al., 1993; Messer and Plummer, 1993). 
Selective damage involving neuronal cells is characteristic for all NCL disorders 
and suggests that NCL proteins may have neuron-specific functions different from 
functions in non-neuronal cells. Possible localization of CLN8 outside the ER in 
neuronal cells supports this hypothesis. Another possibility is that certain 
neuronal populations may be more sensitive to the disturbed function of CLN8.  
 
4.3 Expression analysis of Cln8 in mouse during development 
The tissue expression of Cln8 during development and brain maturation was 
analyzed using radioactive mRNA in situ hybridization analysis and whole embryo 
sections from E13, E15.5 and E17 mice and brain sections from P 0, P 5, P 10 and 
adult mice.  
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In fresh-frozen E13 and E17 embryos the overall expression of Cln8 was low. In 
developing brain some Cln8-specific signal was detected but the expression was 
most prominent in the developing gastrointestinal tract (IV, Fig. 2). Cln8 seems 
to be expressed in all parts of the developing gut suggesting that Cln8 could 
rather have a role in the development of the muscle cell layer or enteric nervous 
system than in the development of the epithelial cell layer. In E17 embryos there 
was also a high expression of Cln8 in the dorsal root ganglion (DRG) neurons (IV, 
Fig. 2). These neurons determine the connections of interneurons and motor 
neurons of the spinal cord. Assuming a role for Cln8 in this process, its disturbed 
function might result in defective connections in DRG with consecutive 
degeneration of motor neurons, the hallmark of mnd mice. In paraffin-embedded 
E15.5 embryos Cln8 expression was detected in the developing gastrointestinal 
tract, adrenal glands and the developing brain, especially in the cortical plate. 
 
Cln8 expression was analyzed in the cortex, cerebellum and hippocampus of P0, 
P5, P10 and adult mice. At P0 Cln8 expression was low but specific in 
hippocampal regions CA1, CA3 and the granular cell layer of the dentate gyrus 
and in the cortex (Fig. 8; IV, Fig. 3). At P5 and P10 Cln8 expression increased in 
the hippocampal regions CA1 (to 115% and 106% of P0) and CA3 (to 139% of P0) 
when compared to P0 (Fig. 8; IV, Fig. 3). In adult mouse brain the expression 
levels of Cln8 were lower in every region when compared to P0, P5 and P10 
suggesting a role for Cln8 in brain maturation (Fig. 8; IV, Fig. 3). This early 
postnatal period is characterized, e.g., by rapid increase in the number of 
synapses (Jacobson, 1991). Expression of Cln8 in cerebellum, only analyzed in 
adult brain, was 156% of Cln8 expression in the cortex. When compared to adult, 
a statistically significant difference in Cln8 expression was detected in the cortex 
at P0, P5 and P10 and in CA3 region at P10 (Fig. 8; IV, Fig. 3). In all maturation 
stages, the expression of Cln8 was highest in the hippocampal region CA3. 
Expression of NCL genes in the brain throughout development and in the mature 
brain indicates that NCL proteins are likely to have roles not only in supporting 
the survival of neurons but also in the differentiation and maturation of different 
neuronal populations during development. Defects in maturation processes could 
lead to neuronal degeneration and loss of neurons. 
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Figure 8. Differential distribution of Cln8 mRNA in the brain at P0, P5, P10 and 
adult mouse analyzed by mRNA in situ hybridization. Optical density values of 
hybridization signals of Cln8 antisense probe are shown as bars in the diagram 
(A=adult). Optical density values of hybridization signals of Cln8 sense probe are 
shown as a gray area behind the bars. In each brain region the optical density 
values at P0, P5 and P10 were compared to the optical density value of adults. 
Symbols, and represent p< 0.05, 0.01 and 0.001, respectively. CX=cortex, 
DG=dentate gyrus 
 
        
 
4.4 Expression analysis of Cln8 in kindling-induced epilepsy 
As epilepsy is an important symptom in human patients, the CNS expression of 
Cln8 mRNA was characterized in the hippocampal electrical kindling model of 
epilepsy, in which repeated electrical stimulations trigger a progressive 
intensification of epileptiform responses, and kindled mice retain an abnormal 
exitability thereafter (Goddard et al., 1969; Dennison et al., 1995). Kindled mice 
were analyzed 2 h, 6 h and 24 h after stimulations and mice with electrodes 
implanted but no electrical stimulations served as controls. Kindling resulted in a 
rapid and long-lasting up-regulation of Cln8 in the brain. After 2 h, 6 h and 24 h 
Cln8 expression in the granular cell layer of the dentate gyrus was 128%, 225% 
and 286% of that in the control mice and in CA3 92%, 114% and 134% of that in 
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the control mice, respectively (Fig. 9; IV, Fig. 4). When compared to controls, a 
statistically significant increase in the expression of Cln8 was detected in all 
hippocampal regions, CA1, CA3 and the granular cell layer of the dentate gyrus, 
after 2 h, 6 h and 24 h (Fig. 9; IV, Fig. 4).  
 
Figure 9. Differential distribution of Cln8 mRNA in the brains of hippocampal 
kindling-induced epileptic mice. Mouse brain sections were analyzed 2 h, 6 h and 
24 h after kindling-induced epileptic seizures by mRNA in situ hybridization. Mice 
with electrodes implanted but no electrical stimulations were used as controls 
(0h). Optical density values of hybridization signals of Cln8 antisense probe are 
shown as bars in the diagram. Optical density values of hybridization signals of 
Cln8 sense probe are shown as a gray area behind the bars. In each brain region 
the optical density values analyzed 2 h, 6 h and 24 h after kindling-induced 
epileptic seizures were compared to control (0h). Symbols, and represent  
p< 0.05, 0.01 and 0.001, respectively.  DG=dentate gyrus 
        
 
Numerous genes are up-regulated or down-regulated in kindled mice and rats. 
For example, the RGS4 gene expression in hippocampus is up-regulated in 
hippocampally kindled mice (Liang and Seyfried, 2001). RGS4 is a member of a 
large RGS protein family and is a key regulator of G-protein signalling (Dohlman 
and Thorner, 1997; Koelle, 1997). RGS4 is suggested to influence brain exitability 
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through multiple processes. Another gene, encoding the α subunit of CaMK II, is 
down-regulated in the hippocampus of hippocampally kindled mice (Liang and 
Seyfried, 2001). CaMK II is a neuronal Ca2+ dependent enzyme, which is suggested 
to influence synaptic transmission and/or neuronal plasticity. 
 
The expression of cathepsin D and Cln1-encoded Ppt1 have been earlier studied 
using Kainic acid (KA)-induced seizures in a rat model. KA is a glutamate analog 
that causes neuronal hyperexcitation and seizures leading to selective and 
delayed neurodegeneration in adult rats (Ben-Ari, 1985). Both show increased 
expression in this model, cathepsin D in the hippocampus, limbic cortex and 
temporo-parieto-occipital neocortex (Hetman et al., 1995) and Ppt1 most 
prominently in pyramidal cells of hippocampal regions CA1 and CA3 (Suopanki et 
al., 2002).  
 
In mnd, pronounced, early accumulation of autofluorescent lipopigment has been 
found in subpopulations of GABAergic neurons, including interneurons, in the 
cortex and hippocampus (Cooper et al., 1999). Staining for phenotypic markers 
have revealed progressive loss of staining in the cortex and hippocampus with 
pronounced hypertrophy of remaining detectable interneurons. In addition to 
mnd, the Cln1 and Cln3 null mice also show a prominent loss of GABAergic 
interneurons (Cooper et al., 1999; Cooper, 2003). These neurons, notably rich in 
mitochondria, have been linked to energy-linked excitotoxicity through 
disturbance of energy metabolism and mitochondrial dysfunctions (Das, 2003). In 
addition, changes in ionotropic glutamate receptors in mnd suggest altered 
glutamatergic neurotransmission (Mennini et al., 2002). Altogether these data 
suggest that NCL proteins may have an important role in protecting neurons from 
excitotoxic insults and further neuronal degeneration.  
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Conclusions and future prospects 
 
In this work the CLN8 gene underlying EPMR was identified and characterized. 
Identification of the EPMR mutation in the CLN8 gene, and the mutation in the 
orthologous mouse Cln8 gene underlying the motor neuron degeneration 
phenotype (mnd), indicated the connection between CLN8 and an NCL phenotype 
in both human and mouse. This connection was further confirmed when four new 
mutations in CLN8 were characterized in a subset of patients of Turkish origin 
with variant late infantile onset NCL phenotype (Ranta et al., 2004). 
Characterization of disease mutations in CLN8 allow molecular confirmation of 
the clinical diagnosis. The mnd mouse model will allow detailed analysis of gene 
expression, behavior, cellular events and disease mechanisms underlying the 
CLN8 defect.  
 
Expression analysis in different human and mouse tissues showed ubiquitous 
expression of CLN8/Cln8 in Northern blot analysis. mRNA in situ hybridization 
analysis of Cln8 CNS expression in mouse during development suggested a role for 
Cln8 in development and maturation of different neuronal populations. Seizure-
induced upregulation of Cln8 in the kindling-induced epilepsy model may indicate 
a protective role for Cln8 during epileptic seizures. 
 
As a first step towards understanding normal and disturbed metabolism of CLN8, 
the subcellular localization of CLN8 in non-neuronal and neuronal cells was 
analyzed. In non-neuronal cells the CLN8 protein is an ER-resident protein which 
partially localizes to the ERGIC. In neuronal cells CLN8 localizes to the ER and 
may partially reside in a subcompartment of the ER or outside the ER. Disease-
causing human mutations studied in this work do not cause mistargeting of CLN8 
in non-neuronal or neuronal cells and thus most likely affect functionally 
important domains of CLN8. In the ER, CLN8 transmembrane protein could have a 
role in e.g. translocation, dislocation, folding, targeting or secretion of other 
proteins. It could also form a channel and have a role in the transfer of other 
proteins or ions through the ER membrane. In light of the findings that CLN8 
belongs to the TCL family of proteins, a role for CLN8 in lipid metabolism is 
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particulary interesting. Different localization in non-neuronal versus neuronal 
cells may indicate a specific role for CLN8 in neurons.     
 
The results of this thesis provide a basis towards understanding the molecular 
pathogenesis of human and mouse NCL phenotypes caused by CLN8 defects. 
However, more studies have to be conducted to resolve the underlying molecular 
mechanisms. Accumulation of storage material in all tissues is characteristic for 
NCLs. However, the neuronal cells are most affected and the mechanisms 
underlying this selective damage still remains an open question. Several 
suggestions can be proposed: neuronal cells can be more vulnerable to the 
storage deposits or NCL proteins could have neuron-specific functions. It has also 
been hypothesized that all NCL proteins could be members of the same 
metabolic pathway. Whether NCL proteins interact directly or indirectly with 
each other still needs to be determined.  
 
Spontaneous and gene-targeted animal models for NCLs as well as the efficient 
use of bioinformatics tools are important in order to resolve the molecular 
mechanisms underlying NCLs. Different applications of microarray technology, 
including gene discovery, predictions of gene function on the basis of specific 
expression patterns, linking cell pathways and drug discovery will have a central 
role in the analysis of animal models. Finally, animal models will be essential in 
the analysis of potential treatment strategies for NCLs. 
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